OA16479A - Pyrazole compounds as CRTH2 antagonists. - Google Patents
Pyrazole compounds as CRTH2 antagonists. Download PDFInfo
- Publication number
- OA16479A OA16479A OA1201300282 OA16479A OA 16479 A OA16479 A OA 16479A OA 1201300282 OA1201300282 OA 1201300282 OA 16479 A OA16479 A OA 16479A
- Authority
- OA
- OAPI
- Prior art keywords
- formula
- alkyl
- pyrazole compounds
- compounds
- alkoxy
- Prior art date
Links
- 150000003217 pyrazoles Chemical class 0.000 title claims abstract description 55
- 230000003042 antagnostic Effects 0.000 title claims description 55
- 239000005557 antagonist Substances 0.000 title claims description 53
- 101710013017 PTGDR2 Proteins 0.000 title claims description 3
- 102100007288 PTGDR2 Human genes 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 134
- 239000000203 mixture Substances 0.000 claims abstract description 78
- 239000000126 substance Substances 0.000 claims abstract description 46
- 239000011780 sodium chloride Substances 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- -1 cyclic amine Chemical class 0.000 claims description 47
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 36
- 206010020751 Hypersensitivity Diseases 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 26
- 230000002401 inhibitory effect Effects 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 14
- 230000002757 inflammatory Effects 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 125000005842 heteroatoms Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 101700070842 CCR3 Proteins 0.000 claims description 8
- 102100005861 CCR3 Human genes 0.000 claims description 8
- YEESKJGWJFYOOK-IJHYULJSSA-N Leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 8
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 7
- 229960001334 Corticosteroids Drugs 0.000 claims description 7
- 210000003491 Skin Anatomy 0.000 claims description 7
- 239000003246 corticosteroid Substances 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 7
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 230000003454 betamimetic Effects 0.000 claims description 6
- 239000000812 cholinergic antagonist Substances 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 101700040666 ACKR2 Proteins 0.000 claims description 5
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 claims description 5
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 5
- 210000001508 Eye Anatomy 0.000 claims description 5
- 210000001503 Joints Anatomy 0.000 claims description 5
- 210000001989 Nasopharynx Anatomy 0.000 claims description 5
- 230000001078 anti-cholinergic Effects 0.000 claims description 5
- 230000004957 immunoregulator effect Effects 0.000 claims description 5
- 200000000018 inflammatory disease Diseases 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 101700043583 CCR5 Proteins 0.000 claims description 4
- 102100012080 CCR5 Human genes 0.000 claims description 4
- 101700076302 CCR9 Proteins 0.000 claims description 4
- 229940121647 EGFR inhibitors Drugs 0.000 claims description 4
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims description 4
- 102000000543 Histamine receptors Human genes 0.000 claims description 4
- 108010002059 Histamine receptors Proteins 0.000 claims description 4
- 206010038683 Respiratory disease Diseases 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 229940093912 Gynecological Sulfonamides Drugs 0.000 claims description 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 2
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 claims description 2
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 229940026752 topical Sulfonamides Drugs 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 102100008149 CCR9 Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 56
- 238000004128 high performance liquid chromatography Methods 0.000 description 42
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 38
- 239000002904 solvent Substances 0.000 description 36
- 210000004027 cells Anatomy 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 29
- 150000003254 radicals Chemical class 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000003643 water by type Substances 0.000 description 24
- 238000004166 bioassay Methods 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- BHMBVRSPMRCCGG-OUTUXVNYSA-N Prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 238000007792 addition Methods 0.000 description 16
- 206010006451 Bronchitis Diseases 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 238000001819 mass spectrum Methods 0.000 description 13
- 208000006673 Asthma Diseases 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 230000002829 reduced Effects 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 10
- 229960001375 Lactose Drugs 0.000 description 10
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 235000011167 hydrochloric acid Nutrition 0.000 description 9
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 239000003380 propellant Substances 0.000 description 9
- 238000002821 scintillation proximity assay Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 206010035742 Pneumonitis Diseases 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000000051 modifying Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 7
- 210000003979 Eosinophils Anatomy 0.000 description 7
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 201000004624 dermatitis Diseases 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 6
- 229910000564 Raney nickel Inorganic materials 0.000 description 6
- 206010039083 Rhinitis Diseases 0.000 description 6
- 210000004241 Th2 Cells Anatomy 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 230000002335 preservative Effects 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 201000009890 sinusitis Diseases 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 210000003651 Basophils Anatomy 0.000 description 5
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 5
- 210000000138 Mast Cells Anatomy 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 150000001735 carboxylic acids Chemical class 0.000 description 5
- 230000001684 chronic Effects 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 231100000406 dermatitis Toxicity 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000001717 pathogenic Effects 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- OHCQJHSOBUTRHG-KGGHGJDLSA-N (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxododecahydro-1H-benzo[f]chromen-5-yl acetate Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- CUTGMYMVYZAKSP-UHFFFAOYSA-N 1-ethyl-5-fluoroindole-2-carboxylic acid Chemical compound FC1=CC=C2N(CC)C(C(O)=O)=CC2=C1 CUTGMYMVYZAKSP-UHFFFAOYSA-N 0.000 description 4
- 102100016910 ACKR2 Human genes 0.000 description 4
- 101710027066 ALB Proteins 0.000 description 4
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 4
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 4
- 108010093579 Arachidonate 5-Lipoxygenase Proteins 0.000 description 4
- OHCQJHSOBUTRHG-ZYIXGEAZSA-N Coleonol Natural products O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@H](O)CCC1(C)C OHCQJHSOBUTRHG-ZYIXGEAZSA-N 0.000 description 4
- 206010016228 Fasciitis Diseases 0.000 description 4
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 4
- 229940093915 Gynecological Organic acids Drugs 0.000 description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- HAEJPQIATWHALX-KQYNXXCUSA-N Inosine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 description 4
- 108009000252 Lung fibrosis Proteins 0.000 description 4
- 235000019759 Maize starch Nutrition 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000111 anti-oxidant Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000001808 coupling Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 201000009910 diseases by infectious agent Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 229930002911 forskolin Natural products 0.000 description 4
- 230000002458 infectious Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 150000002829 nitrogen Chemical group 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 230000000275 pharmacokinetic Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 201000004681 psoriasis Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- TWQCQFRJJOQBRP-UHFFFAOYSA-N 1-(bromomethyl)-2-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(CBr)C(F)=C1 TWQCQFRJJOQBRP-UHFFFAOYSA-N 0.000 description 3
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229960001031 Glucose Drugs 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 3
- 206010046736 Urticarias Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000002009 allergen Effects 0.000 description 3
- 125000004429 atoms Chemical group 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 3
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 201000003883 cystic fibrosis Diseases 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000003301 hydrolyzing Effects 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- LLPCPLUPCKWWFS-UHFFFAOYSA-N methyl 2-[1-[(4-amino-2-fluorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC)C(C)=NN1CC1=CC=C(N)C=C1F LLPCPLUPCKWWFS-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical Effects 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229940037001 sodium edetate Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- HWEZRMYEWACSRM-UHFFFAOYSA-N tert-butyl 2-[1-[(4-aminophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC(C)(C)C)C(C)=NN1CC1=CC=C(N)C=C1 HWEZRMYEWACSRM-UHFFFAOYSA-N 0.000 description 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
- MBLOVZIAFQVXIN-UHFFFAOYSA-N 1-(bromomethyl)-2-chloro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(CBr)C(Cl)=C1 MBLOVZIAFQVXIN-UHFFFAOYSA-N 0.000 description 2
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N 2-Indolecarboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- XKHKQRFISZKFOX-UHFFFAOYSA-N 3-ethyl-5-fluoro-1-benzofuran-2-carboxylic acid Chemical compound C1=C(F)C=C2C(CC)=C(C(O)=O)OC2=C1 XKHKQRFISZKFOX-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical class OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- GMIDGDXRCTUPNM-UHFFFAOYSA-N 5-fluoro-3-methyl-1-benzofuran-2-carboxylic acid Chemical compound C1=C(F)C=C2C(C)=C(C(O)=O)OC2=C1 GMIDGDXRCTUPNM-UHFFFAOYSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N Acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010058284 Allergy to arthropod sting Diseases 0.000 description 2
- 108009000283 Allograft Rejection Proteins 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003441 Asbestosis Diseases 0.000 description 2
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000009137 Behcet Syndrome Diseases 0.000 description 2
- 201000008335 Behcet's disease Diseases 0.000 description 2
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010056695 Bronchial oedema Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108090000426 Caspase 1 Proteins 0.000 description 2
- 208000007451 Chronic Bronchitis Diseases 0.000 description 2
- 206010009137 Chronic sinusitis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000008006 Collagen Disease Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000010247 Contact Dermatitis Diseases 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 208000005679 Eczema Diseases 0.000 description 2
- 206010053776 Eosinophilic cellulitis Diseases 0.000 description 2
- 208000006916 Eosinophilic synovitis Diseases 0.000 description 2
- 206010015226 Erythema nodosum Diseases 0.000 description 2
- 208000004332 Evans Syndrome Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010018651 Graft versus host disease Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000004969 Inflammatory Cells Anatomy 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- 229960001021 Lactose Monohydrate Drugs 0.000 description 2
- 201000009324 Loeffler syndrome Diseases 0.000 description 2
- 206010025135 Lupus erythematosus Diseases 0.000 description 2
- 101700083887 MAPK1 Proteins 0.000 description 2
- 102100016823 MAPK1 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028417 Myasthenia gravis Diseases 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000008425 Protein Deficiency Diseases 0.000 description 2
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 2
- 208000005333 Pulmonary Edema Diseases 0.000 description 2
- 208000009269 Pulmonary Emphysema Diseases 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000006641 Skin Disease Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 208000006045 Spondylarthropathy Diseases 0.000 description 2
- 206010052775 Spondyloarthropathy Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229960004793 Sucrose Drugs 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- 206010043554 Thrombocytopenia Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 229940029983 VITAMINS Drugs 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N Vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 238000003016 alphascreen Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 2
- 244000052616 bacterial pathogens Species 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 230000003435 bronchoconstrictive Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000036232 cellulite Effects 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 201000009151 chronic rhinitis Diseases 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 231100000080 dermatitis contact Toxicity 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 230000003292 diminished Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 231100001003 eczema Toxicity 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- YYPCDTHFNVGHOP-UHFFFAOYSA-N ethyl 2-[1-[(2-chloro-4-nitrophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OCC)C(C)=NN1CC1=CC=C([N+]([O-])=O)C=C1Cl YYPCDTHFNVGHOP-UHFFFAOYSA-N 0.000 description 2
- NNFCNOQLLZRUCS-UHFFFAOYSA-N ethyl 2-[3,5-diethyl-1-[(4-nitrophenyl)methyl]pyrazol-4-yl]acetate Chemical compound CCC1=C(CC(=O)OCC)C(CC)=NN1CC1=CC=C([N+]([O-])=O)C=C1 NNFCNOQLLZRUCS-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002949 hemolytic Effects 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 125000005980 hexynyl group Chemical group 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- WHKGHOQWAPGILZ-UHFFFAOYSA-N methyl 2-(3,5-dimethyl-1H-pyrazol-4-yl)acetate Chemical compound COC(=O)CC=1C(C)=NNC=1C WHKGHOQWAPGILZ-UHFFFAOYSA-N 0.000 description 2
- VZZXVIKHISGIBB-UHFFFAOYSA-N methyl 2-[1-[(2-fluoro-4-nitrophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC)C(C)=NN1CC1=CC=C([N+]([O-])=O)C=C1F VZZXVIKHISGIBB-UHFFFAOYSA-N 0.000 description 2
- IVFWSQIGZRRVKE-UHFFFAOYSA-N methyl 2-[1-[[2-fluoro-4-(1H-indole-2-carbonylamino)phenyl]methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC)C(C)=NN1CC(C(=C1)F)=CC=C1NC(=O)C1=CC2=CC=CC=C2N1 IVFWSQIGZRRVKE-UHFFFAOYSA-N 0.000 description 2
- HPFNUBVNGDFNSK-UHFFFAOYSA-N methyl 2-[1-[[4-[(1-ethyl-5-fluoroindole-2-carbonyl)amino]-2-fluorophenyl]methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound C=1C2=CC(F)=CC=C2N(CC)C=1C(=O)NC(C=C1F)=CC=C1CN1N=C(C)C(CC(=O)OC)=C1C HPFNUBVNGDFNSK-UHFFFAOYSA-N 0.000 description 2
- QZAGGMXFMYZTRA-UHFFFAOYSA-N methyl 2-[1-[[4-[(5-fluoro-3-methyl-1-benzofuran-2-carbonyl)amino]phenyl]methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC)C(C)=NN1CC(C=C1)=CC=C1NC(=O)C1=C(C)C2=CC(F)=CC=C2O1 QZAGGMXFMYZTRA-UHFFFAOYSA-N 0.000 description 2
- KJYUTRXRFOLCDE-UHFFFAOYSA-N methyl 2-[3,5-dimethyl-1-[(4-nitrophenyl)methyl]pyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC)C(C)=NN1CC1=CC=C([N+]([O-])=O)C=C1 KJYUTRXRFOLCDE-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229940113083 morpholine Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000002481 myositis Diseases 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
- 125000005981 pentynyl group Chemical group 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000001263 psoriatic arthritis Diseases 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000010001 silicosis Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 201000009594 systemic scleroderma Diseases 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- NHPZJVXDBAQQMI-UHFFFAOYSA-N tert-butyl 2-(3,5-dimethyl-1H-pyrazol-4-yl)acetate Chemical compound CC1=NNC(C)=C1CC(=O)OC(C)(C)C NHPZJVXDBAQQMI-UHFFFAOYSA-N 0.000 description 2
- MMZSXIHVRVZZPE-UHFFFAOYSA-N tert-butyl 2-(4-fluoro-2-propanoylphenoxy)acetate Chemical compound CCC(=O)C1=CC(F)=CC=C1OCC(=O)OC(C)(C)C MMZSXIHVRVZZPE-UHFFFAOYSA-N 0.000 description 2
- WXKIFZMZYGZRKA-UHFFFAOYSA-N tert-butyl 2-[1-[(2-chloro-4-nitrophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC(C)(C)C)C(C)=NN1CC1=CC=C([N+]([O-])=O)C=C1Cl WXKIFZMZYGZRKA-UHFFFAOYSA-N 0.000 description 2
- JKMPWVZNKPLVTP-UHFFFAOYSA-N tert-butyl 2-[1-[(2-fluoro-4-nitrophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC(C)(C)C)C(C)=NN1CC1=CC=C([N+]([O-])=O)C=C1F JKMPWVZNKPLVTP-UHFFFAOYSA-N 0.000 description 2
- JSMWSXWMVIYJBX-UHFFFAOYSA-N tert-butyl 2-[1-[[4-[(7-chloro-3-methyl-1-benzofuran-2-carbonyl)amino]phenyl]methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC(C)(C)C)C(C)=NN1CC(C=C1)=CC=C1NC(=O)C1=C(C)C2=CC=CC(Cl)=C2O1 JSMWSXWMVIYJBX-UHFFFAOYSA-N 0.000 description 2
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000002689 toll-like receptors Human genes 0.000 description 2
- 108020000411 toll-like receptors Proteins 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 239000002341 toxic gas Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 125000000430 tryptophan group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N (+)-Ascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- CRPTXKKKIGGDBX-UHFFFAOYSA-N (Z)-but-2-ene Chemical compound [CH2]C=CC CRPTXKKKIGGDBX-UHFFFAOYSA-N 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1,2,3-triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-Chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- OFFSPAZVIVZPHU-UHFFFAOYSA-N 1-benzofuran-2-carboxylic acid Chemical class C1=CC=C2OC(C(=O)O)=CC2=C1 OFFSPAZVIVZPHU-UHFFFAOYSA-N 0.000 description 1
- DMMXSSBHARRUHS-UHFFFAOYSA-N 1-benzylindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC=CC=C2N1CC1=CC=CC=C1 DMMXSSBHARRUHS-UHFFFAOYSA-N 0.000 description 1
- OFLCYQKYKQFOIC-UHFFFAOYSA-N 1-butyl-5-fluoroindole-2-carboxylic acid Chemical compound FC1=CC=C2N(CCCC)C(C(O)=O)=CC2=C1 OFLCYQKYKQFOIC-UHFFFAOYSA-N 0.000 description 1
- SPTGDBZPHYIPFD-UHFFFAOYSA-N 1-butylindole-2-carboxylic acid Chemical compound C1=CC=C2N(CCCC)C(C(O)=O)=CC2=C1 SPTGDBZPHYIPFD-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- NNEUCFJEBYTSQT-UHFFFAOYSA-N 1-ethyl-4-fluoroindole-2-carboxylic acid Chemical compound C1=CC=C2N(CC)C(C(O)=O)=CC2=C1F NNEUCFJEBYTSQT-UHFFFAOYSA-N 0.000 description 1
- SHYFQKDFTNPSPH-UHFFFAOYSA-N 1-ethyl-6-fluoroindole-2-carboxylic acid Chemical compound C1=C(F)C=C2N(CC)C(C(O)=O)=CC2=C1 SHYFQKDFTNPSPH-UHFFFAOYSA-N 0.000 description 1
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- NEVFETBXTISVKK-UHFFFAOYSA-N 1-propylindole-2-carboxylic acid Chemical compound C1=CC=C2N(CCC)C(C(O)=O)=CC2=C1 NEVFETBXTISVKK-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- VSRXYLYXIXYEST-KZTWKYQFSA-N 13,14-Dihydro-15-keto-PGD2 Chemical compound CCCCCC(=O)CC[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O VSRXYLYXIXYEST-KZTWKYQFSA-N 0.000 description 1
- INAPMGSXUVUWAF-XCMZKKERSA-N 1D-myo-inositol 6-phosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-XCMZKKERSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 1H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1H-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- FOCKIYZLSZKVDH-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1H-imidazo[4,5-b]pyridine Chemical compound N1C=CC=C2NCNC21 FOCKIYZLSZKVDH-UHFFFAOYSA-N 0.000 description 1
- PLDDTNKKLOTJCZ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1H-pyrazolo[4,3-b]pyridine Chemical compound C1=CNC2CNNC2=C1 PLDDTNKKLOTJCZ-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- PXWJTOHJADWQQO-UHFFFAOYSA-N 2-(1H-pyrazol-4-yl)acetic acid Chemical compound OC(=O)CC=1C=NNC=1 PXWJTOHJADWQQO-UHFFFAOYSA-N 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-Butyne Chemical group CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-Phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- SYOGONCIVFFLHO-UHFFFAOYSA-N 2-[1-[[2-fluoro-4-(1H-indole-2-carbonylamino)phenyl]methyl]-3,5-dimethylpyrazol-4-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C(C)=NN1CC(C(=C1)F)=CC=C1NC(=O)C1=CC2=CC=CC=C2N1 SYOGONCIVFFLHO-UHFFFAOYSA-N 0.000 description 1
- UOKLKYNMKCMIQY-UHFFFAOYSA-N 2-[1-[[2-fluoro-4-[(5-fluoro-3-methyl-1-benzofuran-2-carbonyl)amino]phenyl]methyl]-3,5-dimethylpyrazol-4-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C(C)=NN1CC(C(=C1)F)=CC=C1NC(=O)C1=C(C)C2=CC(F)=CC=C2O1 UOKLKYNMKCMIQY-UHFFFAOYSA-N 0.000 description 1
- QRRQHRRATQZQGH-UHFFFAOYSA-N 2-[1-[[4-[(1-ethyl-5-fluoroindole-2-carbonyl)amino]-2-fluorophenyl]methyl]-3,5-dimethylpyrazol-4-yl]acetic acid Chemical compound C=1C2=CC(F)=CC=C2N(CC)C=1C(=O)NC(C=C1F)=CC=C1CN1N=C(C)C(CC(O)=O)=C1C QRRQHRRATQZQGH-UHFFFAOYSA-N 0.000 description 1
- KGJLBIDTLGWIKS-UHFFFAOYSA-N 2-[1-[[4-[(3-ethyl-5-fluoro-1-benzofuran-2-carbonyl)amino]phenyl]methyl]-3,5-dimethylpyrazol-4-yl]acetic acid Chemical compound O1C2=CC=C(F)C=C2C(CC)=C1C(=O)NC(C=C1)=CC=C1CN1N=C(C)C(CC(O)=O)=C1C KGJLBIDTLGWIKS-UHFFFAOYSA-N 0.000 description 1
- GQUXKUQJYPOKFH-UHFFFAOYSA-N 2-[1-[[4-[(5-fluoro-3-methyl-1-benzofuran-2-carbonyl)amino]phenyl]methyl]-3,5-dimethylpyrazol-4-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C(C)=NN1CC(C=C1)=CC=C1NC(=O)C1=C(C)C2=CC(F)=CC=C2O1 GQUXKUQJYPOKFH-UHFFFAOYSA-N 0.000 description 1
- CANCTKXGRVNXFP-UHFFFAOYSA-N 2-[3-[(4-fluorophenyl)sulfonyl-methylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]acetic acid Chemical compound C1CC(N(C2=CC=CC=C22)CC(O)=O)=C2CC1N(C)S(=O)(=O)C1=CC=C(F)C=C1 CANCTKXGRVNXFP-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- KQGBVVIKMOUTEE-UHFFFAOYSA-N 3-ethyl-5,7-difluoro-1-benzofuran-2-carboxylic acid Chemical compound C1=C(F)C=C2C(CC)=C(C(O)=O)OC2=C1F KQGBVVIKMOUTEE-UHFFFAOYSA-N 0.000 description 1
- ZNSOHODZPOLVGT-UHFFFAOYSA-N 3-ethyl-7-fluoro-1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2C(CC)=C(C(O)=O)OC2=C1F ZNSOHODZPOLVGT-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- IFGJFIJKPJMHES-UHFFFAOYSA-N 5-fluoro-1-propylindole-2-carboxylic acid Chemical compound FC1=CC=C2N(CCC)C(C(O)=O)=CC2=C1 IFGJFIJKPJMHES-UHFFFAOYSA-N 0.000 description 1
- WRLUXNGMPOBMCP-UHFFFAOYSA-N 5-fluoro-3-propyl-1-benzofuran-2-carboxylic acid Chemical compound C1=C(F)C=C2C(CCC)=C(C(O)=O)OC2=C1 WRLUXNGMPOBMCP-UHFFFAOYSA-N 0.000 description 1
- 239000003406 5-lipoxygenase-activating protein inhibitor Substances 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 1
- PWSOSTMTCRJPDX-UHFFFAOYSA-N 6-chloro-1-benzofuran-2-carboxylic acid Chemical compound C1=C(Cl)C=C2OC(C(=O)O)=CC2=C1 PWSOSTMTCRJPDX-UHFFFAOYSA-N 0.000 description 1
- QQMLHVMPKUAVHS-UHFFFAOYSA-N 6-fluoro-1-propylindole-2-carboxylic acid Chemical compound C1=C(F)C=C2N(CCC)C(C(O)=O)=CC2=C1 QQMLHVMPKUAVHS-UHFFFAOYSA-N 0.000 description 1
- ZIDQIOZJEJFMOH-UHFFFAOYSA-N 7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid Chemical compound C1CCCCC1C(O)CCN1C(CCCCCCC(O)=O)C(=O)NC1=O ZIDQIOZJEJFMOH-UHFFFAOYSA-N 0.000 description 1
- GIWYZUBCAKLCAJ-UHFFFAOYSA-N 7-chloro-3-methyl-1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2C(C)=C(C(O)=O)OC2=C1Cl GIWYZUBCAKLCAJ-UHFFFAOYSA-N 0.000 description 1
- 101710026914 AAG Proteins 0.000 description 1
- 101710024119 ABCC4 Proteins 0.000 description 1
- 102100006348 ABCC4 Human genes 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 101710028063 APCS Proteins 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 229940114079 Arachidonic Acid Drugs 0.000 description 1
- 240000007109 Arundinaria gigantea Species 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 108060001001 BRK1 Proteins 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N Bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 101700017623 CALCA Proteins 0.000 description 1
- 101700041770 CALCR Proteins 0.000 description 1
- 102100006374 CASP1 Human genes 0.000 description 1
- 101700083927 CCR1 Proteins 0.000 description 1
- 101700076092 CCR1 Proteins 0.000 description 1
- 102100005860 CCR1 Human genes 0.000 description 1
- 101700024466 CCR10 Proteins 0.000 description 1
- 102100005862 CCR2 Human genes 0.000 description 1
- 101700024589 CCR4 Proteins 0.000 description 1
- 101700019063 CCR6 Proteins 0.000 description 1
- 102100008133 CCR6 Human genes 0.000 description 1
- 102100008151 CCR7 Human genes 0.000 description 1
- 101700029727 CCR8 Proteins 0.000 description 1
- 102100008148 CCR8 Human genes 0.000 description 1
- 101700026482 CCRL2 Proteins 0.000 description 1
- 101700078818 CNOT6 Proteins 0.000 description 1
- 102100017099 CNOT6 Human genes 0.000 description 1
- 108060001945 CRK Proteins 0.000 description 1
- 108060001122 CRTISO Proteins 0.000 description 1
- 102100014440 CX3CR1 Human genes 0.000 description 1
- 101710039744 CX3CR1 Proteins 0.000 description 1
- 229940121384 CXC chemokine receptor type 4 (CXCR4) antagonists Drugs 0.000 description 1
- 102100014035 CXCR1 Human genes 0.000 description 1
- 101700011366 CXCR1 Proteins 0.000 description 1
- 102100014012 CXCR2 Human genes 0.000 description 1
- 101700079756 CXCR3 Proteins 0.000 description 1
- 102100002226 CXCR3 Human genes 0.000 description 1
- 101710025651 CXCR5 Proteins 0.000 description 1
- 102100002072 CXCR5 Human genes 0.000 description 1
- 101700060333 CXCR6 Proteins 0.000 description 1
- 102100002068 CXCR6 Human genes 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229960001927 Cetylpyridinium Chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M Cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
- 229940109275 Cyclamate Drugs 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 102000019460 EC 4.6.1.1 Human genes 0.000 description 1
- 108060000200 EC 4.6.1.1 Proteins 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014952 Eosinophilia myalgia syndrome Diseases 0.000 description 1
- 102100011848 FPR2 Human genes 0.000 description 1
- 101710017954 FPR2 Proteins 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 108091006011 G proteins Proteins 0.000 description 1
- 102000003688 G-protein coupled receptors Human genes 0.000 description 1
- 108090000045 G-protein coupled receptors Proteins 0.000 description 1
- 102000027732 GABAA receptors Human genes 0.000 description 1
- 108091008003 GABAA receptors Proteins 0.000 description 1
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100004115 ICAM1 Human genes 0.000 description 1
- 101710002882 IKBKB Proteins 0.000 description 1
- 102100008724 IKBKB Human genes 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N Indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N Isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 101700057035 KAT5 Proteins 0.000 description 1
- 102100002581 KAT5 Human genes 0.000 description 1
- 102100011311 KNG1 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700048515 LEC1 Proteins 0.000 description 1
- 101700046135 LEC2 Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700028593 LECH Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 102100017376 LTA4H Human genes 0.000 description 1
- 102100002437 LTB4R Human genes 0.000 description 1
- 101710005170 LTB4R Proteins 0.000 description 1
- 102100012770 LTB4R2 Human genes 0.000 description 1
- 101710005169 LTB4R2 Proteins 0.000 description 1
- 206010024377 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 1
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 102000038027 MAP kinase family Human genes 0.000 description 1
- 108091007472 MAP kinase family Proteins 0.000 description 1
- 101710029927 MAPK10 Proteins 0.000 description 1
- 102100005527 MAPK10 Human genes 0.000 description 1
- 102100000918 MAPK14 Human genes 0.000 description 1
- 101710029924 MAPK8 Proteins 0.000 description 1
- 102100005531 MAPK8 Human genes 0.000 description 1
- 102100005528 MAPK9 Human genes 0.000 description 1
- 101710029922 MAPK9 Proteins 0.000 description 1
- 101710026550 MC2R Proteins 0.000 description 1
- 102100003920 MC2R Human genes 0.000 description 1
- 101700013240 MC3R Proteins 0.000 description 1
- 102100002883 MC3R Human genes 0.000 description 1
- 102100002884 MC4R Human genes 0.000 description 1
- 101700072329 MC4R Proteins 0.000 description 1
- 101700036258 MECOM Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002160 Maltose Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
- 102000019623 Melanocortin 5 receptor Human genes 0.000 description 1
- 108090000950 Melanocortin Receptors Proteins 0.000 description 1
- 102000004378 Melanocortin Receptors Human genes 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-M N-benzoylglycinate Chemical compound [O-]C(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-M 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N N-benzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 101700014192 NOCT Proteins 0.000 description 1
- 101700049309 NOS2 Proteins 0.000 description 1
- 102100002496 NOS2 Human genes 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 102100010180 P2RX7 Human genes 0.000 description 1
- 101700064615 P2RX7 Proteins 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 1
- 101710029802 PLA2G4A Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 101710028881 PSAP Proteins 0.000 description 1
- 102100011503 PTGDS Human genes 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 241001506308 Potato virus T Species 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004063 Propylene glycol Drugs 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N Pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 229940043131 Pyroglutamate Drugs 0.000 description 1
- 101700071234 RBG8 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102100003386 S100A12 Human genes 0.000 description 1
- 101710023382 S100A12 Proteins 0.000 description 1
- 102100001435 SH2D1A Human genes 0.000 description 1
- 101710013575 SH2D1A Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N Tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N Tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N Tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N Tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940066528 Trichloroacetate Drugs 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 240000008529 Triticum aestivum Species 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- 208000004762 Vasculitis, Leukocytoclastic, Cutaneous Diseases 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- OWGUSBISUVLUJF-SDNWHVSQSA-N [(E)-(2-hexylcyclopentylidene)amino]thiourea Chemical compound CCCCCCC1CCC\C1=N/NC(N)=S OWGUSBISUVLUJF-SDNWHVSQSA-N 0.000 description 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- JJDZWMVHCHEMCV-UHFFFAOYSA-N azane;ethyne Chemical compound N.[C-]#[C+] JJDZWMVHCHEMCV-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N benzopyran Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- JUPMBRMEHSUGLE-UHFFFAOYSA-N butenyl Chemical compound CCC=[CH] JUPMBRMEHSUGLE-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000001889 chemoattractant Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Substances CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- SNQXJPARXFUULZ-UHFFFAOYSA-N dioxolane Chemical compound C1COOC1 SNQXJPARXFUULZ-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 description 1
- 101710024775 erkB Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- WBMVBANXTDGPMQ-UHFFFAOYSA-N ethyl 2-(3,5-diethyl-1H-pyrazol-4-yl)acetate Chemical compound CCOC(=O)CC=1C(CC)=NNC=1CC WBMVBANXTDGPMQ-UHFFFAOYSA-N 0.000 description 1
- GTIOGABHUHXMNH-UHFFFAOYSA-N ethyl 2-(3,5-dimethyl-1H-pyrazol-4-yl)acetate Chemical compound CCOC(=O)CC=1C(C)=NNC=1C GTIOGABHUHXMNH-UHFFFAOYSA-N 0.000 description 1
- DQZGVLUIYNKISA-UHFFFAOYSA-N ethyl 2-[1-[(4-amino-2-chlorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OCC)C(C)=NN1CC1=CC=C(N)C=C1Cl DQZGVLUIYNKISA-UHFFFAOYSA-N 0.000 description 1
- BQUXWNVZHFZFIL-UHFFFAOYSA-N ethyl 2-[1-[(4-aminophenyl)methyl]-3,5-diethylpyrazol-4-yl]acetate Chemical compound CCC1=C(CC(=O)OCC)C(CC)=NN1CC1=CC=C(N)C=C1 BQUXWNVZHFZFIL-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- KONIYTHNVWYBMP-UHFFFAOYSA-N ethylcyclohexane Chemical compound [CH2-]C[C+]1CCCCC1 KONIYTHNVWYBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 description 1
- 125000006456 halo alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- FJPGAMCQJNLTJC-UHFFFAOYSA-N heptane-2,3-dione Chemical compound CCCCC(=O)C(C)=O FJPGAMCQJNLTJC-UHFFFAOYSA-N 0.000 description 1
- DGCTVLNZTFDPDJ-UHFFFAOYSA-N heptane-3,5-dione Chemical compound CCC(=O)CC(=O)CC DGCTVLNZTFDPDJ-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 201000001431 hyperuricemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative Effects 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- RYMSBRVUHGIBJW-UHFFFAOYSA-N methyl 2-[1-[(4-aminophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC)C(C)=NN1CC1=CC=C(N)C=C1 RYMSBRVUHGIBJW-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 101700019200 mrp4 Proteins 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000002956 necrotizing Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000626 neurodegenerative Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical group NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 1
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002102 polyvinyl toluene Polymers 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001376 precipitating Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108010047707 prostaglandin R2 D-isomerase Proteins 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 101710044770 sll1951 Proteins 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010014501 sphingosine 1-phosphate lyase (aldolase) Proteins 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000008736 systemic mastocytosis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- GXEGVKHZCSNOQI-UHFFFAOYSA-N tert-butyl 2-[1-[(4-amino-2-chlorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC(C)(C)C)C(C)=NN1CC1=CC=C(N)C=C1Cl GXEGVKHZCSNOQI-UHFFFAOYSA-N 0.000 description 1
- QGVIUTZWXKKKIP-UHFFFAOYSA-N tert-butyl 2-[1-[(4-amino-2-fluorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]acetate Chemical compound CC1=C(CC(=O)OC(C)(C)C)C(C)=NN1CC1=CC=C(N)C=C1F QGVIUTZWXKKKIP-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N tetrahydro-2H-thiopyran Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003799 tocopherols Natural products 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-M trichloroacetate Chemical compound [O-]C(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 230000035513 volume of distribution Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021307 wheat Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 1
Abstract
The present invention relates to pyrazole compounds of formula (1a) or (1b) and pharmaceutically acceptable salts thereof,
Description
PYR, \ZOLE COMPOUNDS AS CRTH2 ANTAGONISTS
The présent invention relates to pyrazole compounds of formula (la) or (Ib) and pharmaceutically acceptable salts thereof having CRTH2 antagonistic activity,
wherein Ra, Rb, Rc, Rd, Y1, Y2, Y3, Y4, Y5, Z, R1, R2, n and R3 hâve one of the meanings as indicated in the spécification and claims, to their use as médicaments, to pharmaceutical formulations containing said compounds and to pharmaceutical formulations said compounds in combination with one or more active substances,
BACKGROUND OF THE INVENT ION
Prostaglandin D2 (PGD2) is an eicosanoid generated by the metabolism of arachidonic acids upon stimulation of inflammatory cells with allergens, inflammatory stimuli or by tissue damage, PGD2 is primarily released by mast cells with Th2 cells, dendritic cells, and macrophages being secondary sources. PGD2 is the major arachidonic acid métabolite produced by mast cells upon allergen challenge (Lewis et al,, J, Immunol. 1982, 129:16271631) and has been detected in high concentrations in the airways of asthmatic patients (Murray et al, N. Engl. J. Med., 1986, 315:800-804; Liu et al., Am. Rev. Respir Dis., 1990, 142 126-132; Zehretal., Chest, 1989, 95:1059-63; Wenzel étal., J. Allergy. Clin. Immunol., j
-116479
2/64
1991, 87540-548). PGD2 production is also increased in patients with systemic mastocytosis (Roberts N. Engl. J. Med. 1980, 303, 1400-1404; Butterfield étal., Int Arch Allergy Immunol, 2008,147:338-343) allergie rhinitis (Naclerio et al., Am. Rev. Respir. Dis., 1983, 128:597-602; Brown et al., Arch Otolaryngol Head Neck Surg, 1987,113:179-183; Lebel étal., J. Allergy s Clin. Immunol., 1988, 82:869-877), urticaria (Heavy et al., J. Allergy. Clin. Immunol., 1986, 78:458-461), chronic rhinosinusitis (Yoshimura étal., Allergol. Int., 2008, 57:429-436), chronic obstructive pulmonary disease (Csanky et al., Electrophoresis, 2009, 30:1228-1234) and during anaphylaxis (Ono et al., Clin. Exp. Allergy, 2009, 39:72-80).
io Instillation of PGD2 into airways can provoke features of asthmatic response including bronchoconstriction (Hardy et al., 1984, N Engl J. Med 311:209-213; Sampson et al 1997, Thorax 52: 513-518) and eosinophil accumulation (Emery et al., 1989, J. Applied Physiol 67: 959-962). The potential of PGD2 to trigger inflammatory responses has been confirmed by the overexpression of human PGD2 synthase in mice resulting in elevated eosinophil iung inflammation and Th2 cytokine production in response to allergen (Fujitani et al, 2002 J. Immunol. 168:443-449).
PGD2 is an agonist of two 7-transmembrane type G protein-coupled receptors, the PGD2 receptor DP1 (Boie et al., J Biol Chem, 1995, 270:18910-6) and the recently identified
CRTH2 (chemoattractant receptor-homologous molécule expressed on Th2 cells) receptor (also referred to as DP2 receptor) (Nagata et al., J. Immunol., 1999, 162:1278-86).
CRTH2 is expressed on Th2 cells, eosinophils, basophils and mast cells (Nagata et al., FEBS Lett, 1999, 459: 195-199; Nagata et al., J Immunol, 1999, 162: 1278-1286; Cosmi et 25 al., Eur J Immunol, 2000, 30:2972-2979; Boehme et al., Int Immunol, 2009, 21: 621-32).
Using sélective CRTH2 agonists like 13,14 dihydro-15-keto-PGD2 (DK-PGD2) and 15Rmethyl-PGD2, it has been shown that CRTH2 activation initiâtes cellular processes that lead to the recruitment and activation of inflammatory cells (Spik et al., J. Immunol., 2005;174:3703-8; Shiraishi, J. Pharmacol. Exp. Ther., 2005, 312:954-60; Monneret et al., J.
Pharmacol. Exp. Ther., 2003, 304:349-355). Using CRTH2 sélective antagonists it has been shown that inflammatory responses and pathophysiological changes in animal models of diseases like asthma, allergie rhinitis, atopie dermatitis and COPD can be diminished (Uller et al., Respir Res. 2007, 8:16; Lukacs et al., Am. J. Physiol. Lung Cell Mol. Physiol. 2008,
295:L767-79; Stearns, Bioorg. Med. Chem. Lett. 2009,19:4647-51; Nomiya, J Immunol,
2008, 180:5680-5688; Boehme étal., Int. Immunol., 2009, 21:1-17; Boehme et al., Int
-216479
3/64
Immunol, 2009, 21:81-93; Takeshita et al., Int Immunol, 2004, 16:947-59; Stebbins étal., J. Pharmacol. Exp. Ther. 2009). Moreover, genetic délétion of CRTH2 in mice diminished inflammatory responses in animal models of allergy (Shiraishi et al., J. Immunol. 2008;180:541-549; Oiwa, Clin Exp Allergy, 2008, 38:1357-66; Satoh étal., J. Immunol., 2006,177:2621-9). In contrast, the sélective DP1 agonist BW245C does not promote inflammatory responses, like migration or activation of Th2 lymphocytes, basophils or eosinophils (Yoshimura-Uchiyama et al., Clin. Exp. Allergy, 2004, 34:1283-90; Xue et al., Immunol, 2005, 175:6531-6; Gervais et al., J. Allergy Clin. Immunol., 2001, 108:982-8). Therefore, agents that antagonize the effects of PGD2 at the CRTH2 receptor should be useful for the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints and allergie diseases of the nasopharynx, eyes and skin.
WO 2004/096777 teaches pyrimidine dérivatives of formula (a) and salts thereof,
wherein R6 is carboxy, carboxamide, nitrile or tetrazolyl, said dérivatives having CRTH2 antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity.
WO 2009/042138 daims alkylthio substituted pyrimidine compounds of formula (b),
-316479
4/64 said compounds having CRTH2 antagoniste activity.
WO 2009/042139 claims 2-S-benzyl pyrimidine compounds of formula (c),
said compounds having CRTH2 antagoniste activity.
EP 0 480 659 claims compounds of general formula (d),
Y wherein Z2 inter alia may be carboxyl-C1-C10-alkyl-C= and Y may be substituted benzyl, said compounds being useful for the treatment of hyperuricemia.
WO 2005/040128 claims compounds of general formula (e),
said compounds being useful for the treatment of conditions such as pain, or an inflammatory, immunological, bone, neurodegenerative or rénal disorder.
WO 01/38325 claims compounds of general formula (f),
-416479
5/64 wherein A is an aromatic ring and B is a nitrogen-containing 5-membered hetero ring which may further be substituted, said compounds having hypoglycémie and hypolipidémie activity.
It is an objective of the présent invention to provide further compounds having CRTH2 antagoniste activity.
Preferably the compounds of the présent invention hâve enhanced chemical stability, enhanced pharmacokinetic properties (PK) and/or enhanced activity in a whole cell assay.
DETAILED DESCRIPTION OF THE INVENTION
The présent invention relates to pyrazole compounds of formula (la) or (Ib) and pharmaceutically acceptable salts thereof,
wherein
Ra and Rb are îndependently selected hydrogen, hydroxy, halogen, CrCe-alkyl, CrC6 haloalkyl, CrC6-alkoxy, CrC6-haloalkoxy and C3-Ce-cycloalkyl, or Ra and Rb together 20 with the carbon atom they are bound to form may form a carbonyl group, or Ra and Rb together with the carbon atom they are bound to form a 3- to 8-membered ring, wherein said ring may contain 1 or 2 heteroatoms selected from O, N and S as ring member and wherein the ring members of said ring may optionally be îndependently
-516479
6/64 substituted by hydroxy, halogen, Ci-Ce-alkyl, CrCe-haloalkyl, CrCe-alkoxy, CrC6haloalkoxy and C3-C8-cycloalkyl;
R° and Rd are independently selected hydrogen, hydroxy, halogen, Cf-Ce-alkyi, ΟΊ-ΟΒ5 haloalkyl, CrCB-alkoxy, Ci-C6-haloalkoxy and C3-C8-cycloalky|, or Rc and Rd together with the carbon atom they are bound to form may form a carbonyl group, or Rc and Rd together with the carbon atom they are bound to form a 3- to 8-membered ring, wherein said ring may contain 1 or 2 heteroatoms selected from O, N and S as ring member and wherein the ring members of said ring may optionally be independently io substituted by hydroxy, halogen, CrCe-alkyl, CrCc-haloalkyl, CrCe-alkoxy, CrC6haloalkoxy and C3-Ce-cycloalkyl;
Y1, Y2, Y3, Y4 and Y5 are independently selected from N and CRy, wherein each Ry is independently selected from H, hydroxy, halogen, cyano, nitro, SFs, C(O)NRfR9, Cr 15 C6-alkyl, hydroxy-CrCB-alkyl, CrCe-alkoxy-CrCe-alkyl, C3- Ca-cycloalkyî, Ο,-Οβhaloalkyl, CpCe-alkoxy, Ο,-Ce-alkoxy-Ci-Ce-alkoxy, CrCe-haloalkoxy, C3-C8cycloalkoxy, CrCs-alkylamino, di-CrCe-alkylamino, CrCB-alkylsulfonyl, phenyl, phenoxy, 5- or 6-membered heterocyclyl and 5- or 6-membered heterocyclyloxy, wherein Rf and R9 are independently from each other selected from H, CrCe-alkyl,
CrCe-haloalkyl, C3-Ca-cycloalkyl, C3-C8-cycloalkenyl and 5- or 6-membered heterocyclyl or Rf and R9 together with the nitrogen atom to which they are bound form a cyclic amine, which may comprise a further heteroatom selected from O, N and S as a ring member;
Z is selected from O, S and NRZ, wherein Rz is H, CrCe-alkyl or benzyl;
R1 and R2 are independently from each other selected from H, halogen, CrCB-alkyl, C2-CBalkenyl, C2-C6-alkynyl, Ci-C6-alkoxy, CrCB-alkylthio, -NRfR9, C3-C8-cycloalkyl, C3-CBcycloalkyl-CrCe-alkyl, C3-C8-cycloalkyl-C2-C6-alkenyl, C3-C8-cycloalkenyl, C3-C830 cycloalkenyl-CrCe-alkyl, C3-C6-cycloalkeny!-C2-C6-alkenyl, phenyl, phenyl-CrC6-alkyl, phenyl-C2-C6-alkenyl, naphthyl, naphthyl-CrCe-alkyl, naphthyl-C2-CB-alkenyl, heterocyclyl, heterocyclyî-Ci-CB-alkyl, and heterocyclyl-C2-C6-alkenyl, wherein the CpCe-alkyl, C2-CB-alkenyl and C2-C6-alkynyl moieties in the aforementioned radicale R1 and R2 are unsubstituted or carry at least one substituent selected from
-616479
7/64 hydroxy, halogen, cyano, nitro, CrC6-alkoxy, CrCe-haloalkoxy, Ci-C6-alkylamino, di
Ci-Ce-alkylamino and Ci-C6-alkylsulfonyl and/or wherein two radicals bound to the same carbon atom of said Ci-C6-alkyl, C2-C6alkenyl and C2-C6-alkynyl moieties in the aforementioned radicals R1 and R2 together with said carbon atom may form a carbonyl group, and wherein the C3-C8-cycloalkyl, cycloalkenyl, phenyl, naphthyl and heterocyclyl moieties in the aforementioned radicals R1 and R2 are unsubstituted or carry at least one substituent selected from hydroxy, halogen, cyano, nitro, Ci-C6-alkyl, C3-Ce-cycloalkyl, CrCehaloalkyl, CpCe-alkoxy, CrCe-haloalkoxy, CrCe-alkylamino, di-CrC6-alkylamino, Cr C6-alkylsulfonyl, phenyl and 5- or 6- membered hetaryl and/or wherein two radicals bound to the same carbon atom of said C3-Ce-cycloalkyl, C3-C8cycloalkenyl and heterocyclyl moieties of the radicals R1 and R2 together with said carbon atom may form a carbonyl group, and wherein
Rf and R9 are independently from each other selected from H, CrC6-alkyl, Ci-Cehaloalkyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl and heterocyclyl or
Rr and R9 together with the nitrogen atom to which they are bound form a cyclic amine, which may comprise a further heteroatom selected from O, N and S as a ring member;
n is an integer selected from 0,1, 2 or 3; and
R3 if présent are selected independently from each other from halogen, CrCe-alkyl, Cr C6-haloalkyl, CrC6-alkoxy, Ci-C6-haloalkoxy and C3-C0-cycloalkyl.
Surprisingly it has been found that the compounds of formula (la) or (Ib) according to the présent invention hâve significant CRTH2 antagoniste activity. Further it has been found that said compounds generally hâve enhanced chemical stability, enhanced pharmacokînetic properties (PK) and/or enhanced activity in a whole cell assay.
-716479
8/64
Thus the pyrazole compounds of formula (la) or (Ib) according to the présent invention are suitable for the prévention and/or treatment of diseases related to CRTH2-activity.
Accordingly the présent invention further relates to the use of pyrazole compounds of formula (la) or (Ib) according to the présent invention as médicaments.
Furthermore the présent invention relates to the use of compounds of formula (la) or (Ib) for preparing a médicament for the treatment of diseases related to CRTH2-activity. More specifically the présent invention relates to the use of pyrazole compounds of formula (la) or (lb) for preparing a médicament for the prévention and/or treatment of inflammatory, infectious and immunoregulatory disorders, respiratory or gastrointestinal diseases or complaints, inflammatory diseases of the joints and allergie diseases of the nasopharynx, eyes, and skin.
The présent invention further relates to compounds of formula (la) or (Ib) according to the invention for treating and/or preveting diseases related to CRTH2-activity More specifically the présent invention relates to compounds of formula (la) or (Ib) for use as a médicament for treating diseases related to CRTH2-activity. More specifically the présent invention relates to pyrazole compounds of formula (la) or (Ib) for use as a médicament for the prévention and/or treatment of inflammatory, infectious and immunoregulatory disorders, respiratory or gastrointestinal diseases or complaints, inflammatory diseases of the joints and allergie diseases of the nasopharynx, eyes, and skin.
Furthermore the présent invention relates to pharmaceutical formulations, containing one or more of the pyrazole compounds of formula (la) or (Ib) according to the présent invention as sole active substance or in combination with one or more active substances selected from among betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagoniste, EGFR inhibitors, CCR3 antagoniste, CCR5 antagonists, CCR9 antagonists, 5-LO inhibitors, histamine-receptor antagonists, SYK inhibitors and sulphonamides.
The activity in a whole cell eosinophil shape change assay of the compounds of the invention can be determined, for example, according to the foliowing référencés: (i) Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, Kostenis E. Identification of indol dérivatives exclusively interfering with a G protein-independent signalling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Aug;68(2):393-402; (ii) Schulîgoi R, Schmidt R,
-816479
9/64
Geisslinger G, Kollroser M, Peskar BA, Heinemann A. PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors. Biochem Pharmacol. 2007 Jun 30;74(1 ):107-17; (iii) Royer JF, Schratl P, Carrillo JJ, Jupp R, Barker J, Weyman-Jones C, Beri R, Sargent C, Schmidt JA, Lang-Loidolt D, Heinemann A. A novel antagonïst of prostaglandin D2 blocks the locomotion of eosinophils and basophils. Eur J Clin Invest. 2008 Sep;38(9):663-71.
The chemical stability of the compounds of the invention can be determined, for example, under the following conditions: (i) 3 days incubation at 60°C in 0.1 N HCl (hydrolytic stability under acide conditions); (ii) 3 days incubation at 60°C in pH 4.0 buffer solution (hydrolytic stability under weakly acidic conditions); (iii) 3 days incubation at 60°C in pH 7.4 buffer solution (hydrolytic stability at physiological pH); (iv) 3 days incubation at 20°C in 0.3 % hydrogen peroxide (stability against oxidants); (v) 24 h incubation under UV-radiation (lambda = 300 - 800 nm, P = 250 W/m2) in water (stability against light). The kinetics of dégradation can, for example, be determined by HPLC analysis.
The pharmacokïnetic properties (PK) of the compounds of the invention can be determined in pre-clinical animal species, for example, mouse, rat, dog, guinea pig, mini pig, cynomolgus monkey, rhésus monkey. The pharmacokïnetic properties of a compound can be described, for example, by the following parameters: Mean résidence time, half-life, volume-ofdistribution, AUC (area under the curve), clearance, bioavailability after oral administration.
USED TERMS AND DEFINITIONS
Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the spécification, however, unless specified to the contrary, the following terms hâve the meaning indicated and the following conventions are adhered to.
In the groups, radicals or moieties defined below, the number of carbon atoms is often specified preceding the group. As an example Ci-Ce-alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
In general, for groups comprising two or more subgroups, the last named group is the radical attachment point.
-916479
10/64
Unless otherwise specified, conventional définitions of terms control and conventional stable atom valences are presumed and achieved in ail formulas and groups.
In general ail tautomeric forms and isomeric forms and mixtures, whether individual géométrie isomers or optical isomers or racemic or non-racemic mixtures of isomers of a chemical structure or compound, are comprised, unless the spécifie stereochemistry or isomeric form is speeifically indicated in the compound name or structure.
The term substituted as used herein, means that any one or more hydrogens on the designated atom, moiety or radical is replaced with a sélection from the indicated group of radicals, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.
The compounds disclosed herein can exist as pharmaceutically acceptable salts. The présent invention includes compounds in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the préparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complété discussion of the préparation and sélection of salts, refer to Pharmaceutical Salts: Properties, Sélection, and Use (Stahl, P. Heinrich. Wiley-VCH, Zurich, Switzerland, 2002).
The term pharmaceutically acceptable sait, as used herein, represents salts or zwitterionic forms ofthe compounds disclosed herein which are water oroil-soluble or dispersible and pharmaceutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Représentative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphor sulfonate, citrate, digluconate, formate, fumarate, gentîsate, glutarate, glycérophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylene sulfonate, methane sulfonate, naphthylene sulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, υνζ'
-1016479
11/64 pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, and organic acids such as oxalic acid, maleic acid, succinic acid and citrïc acid. Salts can also be formed by coordination of the compounds with an alkali métal or alkaline earth ion. Hence, the présent invention comprises sodium, potassium, magnésium, and calcium salts of the compounds disclosed herein, and the like.
Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a métal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of pharmaceutically acceptable salts include lithium, sodium, potassium, calcium, magnésium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tétraméthylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, Ν,Ν-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, Ν,Ν-dibenzylphenethylamine, 1-ephenamine, and Ν,Ν'-dibenzylethylenediamine. Other représentative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine and piperazine.
While it may be possible for the compounds of the présent invention to be administered as the raw chemical, it is also possible to présent them as a pharmaceutical formulation. Accordingly, provided herein are pharmaceutical formulations which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvatés thereof, together with one or more pharmaceutically acceptable carrier and optionally one or more other therapeutic ingrédients. The carrier(s) must be acceptable in the sense of being compatible with the other ingrédients of the formulation and not deleterious to the récipient thereof. Proper formulation is dépendent upon the route of administration chosen. Any ofthe well-known techniques, carriers and xfi/'
-1116479
12/64 excipients may be used as suitable and as understood in the art; e.g. in Remington's Pharmaceutical Sciences. The pharmaceutical compositions disclosed herein may be manufactured in any manner known în the art, e.g., by means of conventional mixing, dissolving, granulatrng, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
The term halogen as used herein dénotés a halogen substituent selected from fluoro, chloro, bromo or iodo.
The term CrCe-alkyl as used herein (including the alkyl moieties of CrCe-alkoxy, CrCe-alkylamino, di-CrCe-alkylamino, C-i-Ce-alkylthio and the like) dénotés branched and unbranched alkyl moieties with 1 to 6 carbon atoms attached to the remaining compound at any position of the alkyl chain. The term CrC4 -alkyl accordingly dénotés a branched or unbranched alkyl moiety with 1 to 4 carbon atoms. -alkyl is generally preferred. Examples of Ci-C6-alkyl include: methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, secbutyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl or hexyl. Unless stated otherwise, the définitions propyl, butyl, pentyl and hexyl include ail the possible isomeric forms of the groups in question. Thus, for example, propyl includes n-propyl and iso-propyl, butyl includes isobutyl, sec-butyl and tert-butyl etc.
The term CrCe-haloalkyl as used herein (including the alkyl moieties of CrC6-haloalkoxy, CrCe-haloalkylamino, di-CrCe-haloalkylamino, CrCe-haloalkylthio and the like) dénotés branched and unbranched alkyl moieties with 1 to 6 carbon atoms wherein one or more hydrogen atoms are replaced by a halogen atom selected from among fluorine, chlorine or bromine, preferably fluorine and chlorine, particularly preferably fluorine. The term Ci-C4-haloalkyl accordingly dénotés branched and unbranched alkyl moieties with 1 to 4 carbon atoms, wherein one or more hydrogen atoms are replaced analogously to what was stated above. C^C^-haloalkyl is generally preferred. Preferred examples include: CH2F, CHF2 and CF3.
The term C2-C6-alkenyr as used herein (including the alkenyl moieties of other radicals) dénotés branched and unbranched alkenyl groups with 2 to 6 carbon atoms attached to the remaining compound at any position of the alkenyl chain and having at least one double bond. The term C2-C4-alkenyl accordingly dénotés branched and unbranched alkenyl moieties with 2 to 4 carbon atoms. Preferred are alkenyl moieties with 2 to 4 carbon atoms. fjy'
-1216479
13/64
Examples include: ethenyl or vinyl, propenyl, butenyl, pentenyl or hexenyl. Unless otherwise stated, the définitions propenyl, butenyl, pentenyl and hexenyl include ail possible isomeric forms of the moieties in question. Thus, for example, propenyl includes 1-propenyl and 2propenyl, butenyl includes 1-, 2-and 3-butenyl, 1-methyl-1 -propenyl, 1-methyl-2-propenyl etc.
The term C2-C6-alkynyr' as used herein (including the alkynyl moieties of other radicals) dénotés branched and unbranched alkynyl groups with 2 to 6 carbon atoms attached to the remaining compound at any position of the alkynyl chain and having at least one triple bond. The term C2-C4-alkynyl accordingly dénotés branched and unbranched alkynyl moieties with 2 to 4 carbon atoms. Alkynyl moieties with 2 to 4 carbon atoms are preferred. Examples include: ethynyl, propynyl, butynyl, pentynyl, or hexynyl. Unless stated otherwise, the définitions propynyl, butynyl, pentynyl and hexynyl include ail the possible isomeric forms of the respective moieties. Thus, for example, propynyl includes 1-propynyl and 2-propynyl, butynyl includes 1-, 2- and 3-butynyl, 1-methyl-1-propynyl, 1-methyl-2-propynyl etc.
The term C3-C8-cycloalkyl as used herein (including the cycloalkyl moieties of other radicals) dénotés cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycîoheptyl and cyclooctyl. Preferred are cyclic alkyl groups with 3 to 6 carbon atoms, such as cyclopropyl, cyclopentyl and cyclohexyl.
The term C3-C8“Cycloalkenyl as used herein (including the cycloalkenyl moieties of other radicals) dénotés carbocyclic radicals having 3 to 8 carbon atoms and containing at least one, preferabiy one or two, non-conjugated double bonds. Examples are cyclopentenyl, cyclopantadienyl, cyclohexenyl and cyclohexadienyl.
The term heterocyclyl as used herein (including the heterocyclyl moieties of other radicals) dénotés 5- to 7-membered heterocyclic radicals and 5-to10-membered, bicyclic heterocyclic radicals, containing one, two or three heteroatoms, selected from O, N and S as ring members. The heterocyclyl may be linked to the molécule by a carbon atom or, if présent, by a nitrogen atom. The term heterocyclyl as used herein encompasses saturated or partially unsaturated heterocyclyl as well as hetaryl.
The term saturated or partially unsaturated heterocyclyl as used herein (including the heterocyclyl moieties of other radicals) dénotés 5- to 7-membered monocyclic heterocyclic
-1316479
14/64 radicals as defined above containing a number of double bonds such that no aromatic system is formed as well as 5- to 10-membered bicyclic heterocyclic radicals as defined above containing a number of double bonds such that no aromatic system is formed in at least one of the cycles.
Examples of monocyclic saturated or partially unsaturated heterocyclyl include pyrrolîdine, tetrahydrofurane, tetrahydrothiophene, thiazolidine, dioxolane, piperidine, tetrahydropyrane, tetrahydrothiopyrane, piperazine, morpholine, thiomorpholine, oxazepane, and the like.
Examples of bicyclic saturated or partially unsaturated heterocyclyl include dihydropyrrolizine, pyrrolizine, tetrahydroquinoline, tetrahydroisoquinoline, tetrahydroimidazopyridine, tetrahydropyrazolopyridine, benzopyrane, benzodiazépine, and the like.
The term hetaryl as used herein (including the heterocyclyl moieties of other radicals) dénotés 5- to 7-membered monocyclic heterocyclic radicals as defined above containing a number of double bonds such that an aromatic system is formed as well as 5- to 10membered bicyclic heterocyclic radicals as defined above containing a number of double bonds such that an aromatic system is formed in both cycles.
Examples of monocyclic aromatic heterocyclyl include furan, thiazole, pyrrole, thiophene, pyrazole, imidazole, thiadiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, oxazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and the like.
Examples of bicyclic aromatic heterocyclyl include pyrrolizine, indol, indolizine, isoindol, indazol, purine, quinoline, isoquinoline, benzimidazol, benzofuran, benzothiazol, benzoisothiazol, pyridopyrimidine, pteridine, pyrimidopyrimidine, imidazopyridine, pyrazolopyridîne, and the like.
The term fused carbocyclic or heterocyclic moiety as used herein dénotés C3-Ce-cycloalkyl, C3-Ca-cycloalkenyl, benzene and heterocyclyl moieties as defined above, wherein said moieties share at least one bond with the cyclic moiety they are bound to. As an example benzene fused to benzene is naphthalene. Preferred are fused cyclic moieties sharing one bond with the cyclic moiety they are fused to. Further preferred the fused moiety is benzene.
-1416479
15/64
The term 3- to 8-membered ring formed by two radicals together with the carbon atom they are bound, wherein said ring may contain 1 or 2 heteroatoms selected from O, N and S as ring member as used herein dénotés C3-Ca-cycloalkyl, C3-C8-cycloalkenyl and heterocyclyl moieties as defined above.
The term cyclic amine formed by two radicals together with the nitrogen atom to which they are bound, wherein said ring may comprise a further heteroatom selected from O, N and S as a ring member as used herein dénotés cyclic amines having 3 to 8, preferably 5 or 6, ring members. Examples of such formed amines are pyrrolidine, piperidine, piperazîne, morpholine, pyrrol, imidazole, and the like.
The terms heterocyclyl-Ci-C6-alkyl, ^-Ca-cycloalkyl-CrCe-alkyl, phenyl-Ci-C6-alkyl and naphthyl-Ci-C6-alkyr as used herein dénoté alkyl moieties as defined above having 1 to 6 carbon atoms, wherein any one of the hydrogen atoms is replaced by a cyclic moiety as defined above. In these terms the alkyl moiety preferably has 1 to 4 carbon atoms (C1-C4alkyl). More preferably the alkyl moiety is methyl or ethyl, and most preferred methyl. Preferred examples of phenyl-CrC6-alkyl are benzyl or phenethyl.
The terms heterocyclyl-C2-C6-alkenyr, C3-Ce-cycloalkyl-C2-C6-alkenyl, phenyl-C2-C6alkenyl and naphthyl-C2-C6-alkenyl as used herein dénoté alkenyl moieties as defined above having 2 to 6 carbon atoms, wherein any one of the hydrogen atoms is replaced by a cyclic moiety as defined above. In these terms the alkenyl moiety preferably has 2 to 4 carbon atoms (C2-C4-alkenyl). More preferably the alkenyl moiety is ethenyl. A preferred example of phenyl-C2-C6-alkenyl is phenethenyl.
The spécifie and preferred définitions given for the indivîdual radicals and moieties Ra, Rb, Rc, Rd, Y1, Y2, Y3, Y4, Y5, Z, R1, R2, n and R3 herein below are valuable on their own as well as in combination. As will be understood preferred are compounds of formula (la) or (Ib) wherein one ore more ofthe indivîdual radicals and moieties Ra, Rb, Rc, Rd, Y1, Y2, Y3, Y4, Y5, Z, R1, R2, n and R3 hâve one of the meanings indicated as preferred herein-below and wherein the remaining radicals and moitiés are as specified hereinbefore. Most preferred are compounds of formula (la) or (Ib) wherein ail of the indivîdual radicals and moieties Ra, Rb, Rc, Rd, Y1, Y2, Y3, Y4, Y5, Z, R’, R2, n and R3 hâve one ofthe meanings indicated as preferred herein-below.
-1516479
16/64
One particular embodiment of the invention relates to pyrazole compounds of formula (la), wherein the individual moieties hâve one of the meanings given in the spécification. Preferred are compounds of formula (la), wherein the individual moieties hâve one of the preferred meanings given in the spécification.
Another particular embodiment of the invention relates to pyrazole compounds of formula (lb), wherein the individual moieties hâve one of the meanings given in the spécification. Preferred are compounds of formula (lb), wherein the individual moieties hâve one ofthe preferred meanings given in the spécification.
Preferred are pyrazole compounds of formula (la) or (lb), wherein Ra and Rb are independently selected hydrogen, CrCe-alkyl, Ci-C6 haloalkyl and C3-C8-cycloalkyl.
Particularly preferred are pyrazole compounds of formula (la) or (lb), wherein Ra and Rb are both hydrogen.
Likewise preferred are pyrazole compounds of formula (la) or (lb), wherein Rc and Rd are independently selected hydrogen, CrC6-alkyl, CrCo-haloalkyl and C3-Cfl-cycloalkyl.
Particularly preferred are pyrazole compounds of formula (la) or (lb), wherein Rc and Rd are both hydrogen.
Likewise preferred are pyrazole compounds of formula (la) or (lb), wherein Y1 is CRy1 or N, wherein R*1 has one of the meanings given for R*.
More preferred are pyrazole compounds of formula (la) or (lb), wherein Y1 is CRy1, in particular wherein Ry1 is selected from H, Ci-C6-alkyl, CrC6-alkoxy-CrC6-alkyl and Ci-C6haloalkyl.
Likewise preferred are pyrazole compounds of formula (la) or (lb), wherein Y2 is CR1'2, Y3 is CR*3, Y4 is CRy4 and/or Y5 is CR*5, wherein R*2, Ry3, Ry4 and R*5 independently from each other hâve one of the meanings as defined for Ry.
More preferred are pyrazole compounds of formula (la) or (lb), wherein Y2 is CR*2, Y3 is CR*3, Y4 is CR*4 and Y5 is CR*5, wherein R*2, R*3, R*4 and R*5 independently from each other
-1616479
17/64 hâve one of the meanings as defined for R¥, in particular wherein R1*2, Ry3, Ry4 and Ry5 are independently selected from H, halogen, CrCg-alkoxy, Ci-C6-alkoxy-CrC6-alkoxy and CrC6haloalkoxy.
One particular embodiment of the invention relates to pyrazole compounds of formula (la) or (Ib), wherein Z is O and the remaining moieties hâve one of the meanings given in the spécification, preferably one of the preferred meanings given in the spécification.
Another particular embodiment of the invetion relates to pyrazole compounds of formula (la) or (Ib), wherein Z is S and the remaining moieties hâve one of the meanings given in the spécification, preferably one of the preferred meanings given in the spécification.
Another particular embodiment of the invention relates to pyrazole compounds of formula (la) or (Ib), wherein Z is NRZ, wherein Rz is H, CrC6-alkyl or benzyl, and the remaining moieties hâve one of the meanings given in the spécification, preferably one of the preferred meanings given in the spécification.
Likewise preferred are pyrazole compounds of formula (la) or (Ib), wherein R1 and R2 independently from each other are selected from H, CrC6-alkyl, C3-Ca-cycloalkyl, phenyl and naphthyl.
More preferred are pyrazole compounds of formula (la) or (Ib), wherein R1 and R2 independently from each other are selected from H, CrC4-alkyl, C3-C6-cycloalkyl and phenyl.
Particularly preferred are pyrazole compounds of formula (la) or (Ib), wherein R1 and R2 are selected from CrC4-alkyl.
Likewise preferred are pyrazole compounds of formula (la) or (Ib), wherein n is 0, 1, 2 or 3, in particular wherein n is 0 or 1.
Likewise preferred are pyrazole compounds of formula (la) or (Ib), wherein R3 if présent are independently selected from halogen, Ct-CG-alkoxy and CrC6-haloalkoxy.
More preferred are pyrazole compounds of formula (la) or (Ib), wherein R3 if présent are independently selected from halogen, in particular from F, Cl and Br. y\/--1716479
18/64
One preferred particular embodiment of the invention relates to pyrazole compounds selected from compounds of formula (la j,
wherein Z, R1, R2, R3, Ry1, R*2, Ry3, Ry4 and R*5 hâve one of the meanings given above and n is 0 or 1.
More preferred are pyrazole compounds (la j wherein at least one of the moieties Z, R1, R2, R3, Ry1, Ry2. R*3, Ry4 and R*5 hâve one of the preferred meanings given above.
Another preferred particular embodiment of the invention relates to pyrazole compounds selected from compounds of formula (Ib1),
wherein Z, R1, R2, R3, Ry1, Ry2, R*3, Ry4 and R1* hâve one of the meanings given above.
More preferred are pyrazole compounds (laj wherein at leastone of the moieties Z, R1, R2, R3, Ry1, R*2, Ry3, Ry4 and R^ hâve one of the preferred meanings given above.
A further embodiment of the présent invention relates to compounds of formula (la) or (Ib), wherein the compounds of formula (la) or (Ib) are présent in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, preferably in the form of the enantiomerically pure compounds.
-1816479
19/64
A further embodiment of the présent invention relates to compounds of formula (la) or (lb), wherein the compounds of formula (la) or (lb) are présent in the form of the acid addition salts thereof with pharmacologically acceptable acids as well as optionally in the form of the solvatés and/or hydrates.
PREPARATION
The compounds according to the invention may be obtained using methods of synthesis which are known to a person skilled in the art and described in the literature of organic synthesis. Preferably the compounds are obtained analogously to the methods of préparation explained more fully hereinafter, in particular as described in the experimental section.
Compounds of formula (la) according to the présent inventioncan be prepared according to scheme 1.
Scheme 1
Starting material I
Starting material II
-1916479
20/64
(Deprotection) (la)
According to scheme 1 the compounds of the présent invention can be prepared employing as starting material I (1H-pyrazol-4-yl)acetic acid dérivatives, which are substituted with substituents Ra, Rb, R1, R2 and with a carboxylic acid protecting group PG. These compounds can, in some cases, be obtained from commercial sources or can be prepared according to literature procedures, for example WO 2007/141267. Suitable protecting groups can be selected from T. W. Greene, Protective Groups in Organic Synthesis, Wiley, 3fd édition, 1999. Preferred protecting groups PG are methyl, ethyl, tert-butyl.
Intermediate I can be obtained by alkylation of starting material I with a suitable 4-nitrobenzyl compounds as starting material II, wherein LG is a suitable leaving group such as halogen, in particular Br, or mesylate, in the presence of a base. Suitable bases are inorganic bases such as carbonates, especially potassium carbonate. The reaction is preferably carried out in an organic solvent such as dimethylformamide, dimethylsulfoxid, acetonitrile, tetrahydrofuran, dichloromethane or a mixture of solvents. The reaction usually takes place within 1 to 48 hours. Preferred reaction températures are between 0°C and the boiling point of the reaction mixture. When R1 is different from R2, the alkylation reaction may yield a mixture of regioisomers. The individual isomers may be separated by methods which are known to a person skilled in the art, for example, chromatography over silica gel employing a suitable solvent or solvent mixtures, or préparative reversed phase chromatography, employing a suitable gradient of solvents, or trituration or crystallization from suitable solvents or solvent mixtures.
Amine intermediate II can be prepared from intermediate I by réduction of the nitro group, for instance by hydrogenolysis in the presence of a catalyst, such as palladium on carbon or Raney Nickel. The réaction is preferably carried out in an inert organic solvent, such as methanol, éthanol, acetic acid, ethyl acetate or a mixture of solvents. The reaction usually takes place within 1 to 48 hours. Preferred reaction températures are between 0°C and 50°C.
-2016479
21/64
Preferred reaction pressures are between atmospheric pressure and 100 bar. The réduction ofthe nitro group in intermediate II can also be carried out according to alternative methods described in J. March, Advanced Organic Chemistry, Wiley, 4111 édition, 1992, p. 1216-1217. Amide intermediate III can be prepared from amine intermediate II by coupling with a carboxylic acid (Starting Material III) in the presence of a coupling reagent, such as 2-(1Hbenzotriazole-l-yh-IJ.S.S-tetramethyluronium tetrafluoroborate (TBTU), and a base, such as diisopropylethylamine. The reaction is preferably carried out in an inert organic solvent, such as dimethylformamide, tetrahydrofuran, dichloromethane or a mixture of solvents. The reaction usually takes place within 1 to 48 hours. Preferred reaction températures are between 0°C and 30°C. The coupling of a carboxylic acid to the amino group of intermediate III can also be carried out according to alternative methods described in J. March, Advanced Organic Chemistry, Wiley, 4’h édition, 1992, p. 419-421. Alternatively, instead of the carboxylic acid (starting material III) and a coupling reagent, the corresponding acyl chloride or anhydride may be employed.
Compounds of formula (la) can be obtained from intermediate III by removal ofthe protecting group PG. In the case the hydroxycarbonyl group is protected by CH3 or C2H5, this conversion can be carried out under aqueous conditions in the presence of an inorganic base, such as NaOH or LiOH. The reaction is preferably carried out in water or a mixture of water with CH3OH, C2H5OH, tetrahydrofuran or dioxane. The reaction usually takes place within 1 to 48 hours. Preferred reaction températures are between 0°C and the boiling point of the reaction mixture. In the case that PG is tert-butyl, the deprotection can be carried out under acidic conditions, for instance with trifluoroacetic acid, hydrochloric acid or montmorillonit. When using trifluoroacetic acid, the réaction can be carried out in neat trifluoroacetic acid or in an inert solvent, such as dichloromethane. The réaction usually takes place within 1 to 48 hours. Preferred reaction températures are between 0qC and 30°C. The cleavage of the protecting group PG may also be carried out according to alternative methods described in J. March, Advanced Organic Chemistry, Wiley, 4lh édition, 1992, p. 378-383 or in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, 3rd édition, 1999.
Compounds of formula (Ib) can be obtained following the procedure depicted in scheme I using starting material of formula III', wherein
-2116479
22/64
Starting material III'
Y1, Y2, Y3, Y4, Y5 and Z hâve one of the meanings indicated above, instead of starting material III.
INDICATIONS
The compounds of formula (la) or (lb) according to the présent invention are especially useful for manufacturing a médicament for the prévention and/or treatment of diseases wherein the activity of a CRTH2-receptor is involved.
One embodiment of the présent invention relates to the manufacturing of a médicament for the prévention and/or treatment of a wide variety of inflammatory, infectious, and immunoregulatory disorders, respiratory or gastrointestinal diseases or complaints, inflammatory diseases of the joints and allergie diseases of the nasopharynx, eyes, and skin. Such disorders diseases and complaints include asthma and allergie diseases, éosinophilie diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes (which, by définition, includes viruses), as well as autoimmune pathologies, such as the rheumatoid arthritis and atherosclerosis.
Preferred is the manufacturing of a médicament for the prévention and/or treatment of inflammatory or allergie diseases and conditions, including allergie or ποη-allergic rhinitis or sinusitis, chronic sinusitis or rhinitis, nasal polyposis, chronic rhinosinusitis, acute rhinosinusitis, asthma, pédiatrie asthma, allergie bronchitis, alveolitïs, Farmer’s disease, hyperreactive airways, allergie conjunctivitis, bronchitis or pneumonitis caused by infection, e.g. by bacteria or viruses or helminthes or fungi or protozoons or other pathogens, bronchiectasis, adult respiratory distress syndrome, bronchial and pulmonary edema, bronchitis or pneumonitis or interstitial pneumonitis caused by different origins, e.g. aspiration, inhalation of toxic gases, vapors, bronchitis or pneumonitis or interstitial pneumonitis caused by heart faîlure, X-rays, radiation, chemotherapy, bronchitis or pneumonitis or interstitial pneumonitis associated with collagenosis, e.g. lupus erythematodes, systemic scleroderma, lung fibrosis, idîopathic pulmonary lung fibrosis (IPF),
-2216479
23/64 interstitial lung diseases or interstitial pneumonitis of different origin, including asbestosis, silicosis, m. Boeck or sarcoidosis, granulomatosis, cystic fïbrosis or mucoviscidosis, or a1antitrypsin deficiency, éosinophilie cellulites (e.g., Well's syndrome), éosinophilie pneumonias (e.g., Loeffler’s syndrome, chronic éosinophilie pneumonia), éosinophilie fasciitis (e. g., Shulman’s syndrome), delayed-type hypersensitivity, non-allergic asthma; exercise induced bronchoconstriction; chronic obstructive pulmonary disease (COPD), acute bronchitis, chronic bronchitis, cough, pulmonary emphysema; systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporin), eosinophilia-myalgia syndrome due to the ingestion of contaminated tryptophane, insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, immune thrombocytopenia (adult ITP, néonatal thrombocytopenia, pédiatrie ITP), immune hemolytic anémia (auto-immune and drug induced), Evans syndrome (platelet and red cell immune cytopaenias), Rh disease of the newborn, Goodpasture’s syndrome (anti-GBM disease), Celiac, autoimmune cardiomyopathy juvénile onset diabètes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g., in transplantation), including allograft rejection or graftversushost disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as an dermatitis, eczema, atopie dermatitis, allergie contact dermatitis, urticaria; vasculitis (e. g., necrotizing, cutaneous, and hypersensitivity vasculitis); erythema nodosum; éosinophilie myositis, éosinophilie fasciitis, cancers with leukocyte infiltration of the skin or organs.
METHOD OF TREATMENT
Accordingly, the compounds of formula (la) or (lb) according to the présent invention are useful in the prévention and/or treatment of a wide variety of inflammatory, infectious, and immunoregulatory disorders and diseases. Such disorders and diseases include but are not limited to asthma and allergie diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes (which, by définition, includes viruses), autoimmune pathologies such as the rheumatoid arthritis and atherosclerosis.
As an example, an instant compound of formula (la) or (lb) which inhibits one or more functions of a mammalian CRTH2 receptor (e. g., a human CRTH2 receptor) may be administered to inhibit (i.e., reduce or prevent) inflammation and bronchoconstriction. As a «a.
-2316479
24/64 resuit, one or more inflammatory processes, such as leukocyte émigration, adhesion, chemotaxis, exocytosis (e. g., of enzymes, growth factors, histamine, cytotoxic proteins), inflammatory mediator release, survival or prolifération of CRTH2 expressing cells is inhibited. For example, activation or recruitment of Th2 cells, mast cells, basophils and éosinophilie to inflammatory sites (e. g., in asthma or allergie rhinitis) can be inhibited according to the présent method.
In particular, the compounds of the following examples hâve activity in blocking the activation and migration of cells expressing the CRTH2 receptor using the appropriate CRTH2 agonists in the aforementioned assays.
Diseases or conditions of humans which can be treated with inhibitors of CRTH2 receptor function, include, but are not limited to inflammatory or allergie diseases and conditions, including allergie or non-allergic rhinitis or sinusitis, chronic sinusitis or rhinitis, nasal polyposis, chronic rhinosinusitis, acute rhinosinusitis, asthma, pédiatrie asthma, allergie bronchitis, alveolitis, Farmer’s disease, hyperreactive airways, allergie conjunctivitis, bronchitis or pneumonitis caused by infection, e.g. by bacteria or viruses or helminthes or fungi or protozoons or other pathogens, bronchiectasis, adult respiratory distress syndrome, bronchial and pulmonary edema, bronchitis or pneumonitis or interstitial pneumonitis caused by different origins, e.g. aspiration, inhalation of toxic gases, vapors, bronchitis or pneumonitis or interstitial pneumonitis caused by heart failure, X-rays, radiation, chemotherapy, bronchitis or pneumonitis or interstitial pneumonitis associated with collagenosis, e.g. lupus erythematodes, systemic scleroderma, lung fibrosis, idiopathic pulmonary lung fibrosis (IPF), interstitial lung diseases or interstitial pneumonitis of different origin, including asbestosis, silicosis, m. Boeck or sarcoidosis, granulomatosis, cystic fibrosis or mucoviscidosis, or a1-antitrypsin deficiency, éosinophilie cellulites (e.g. Well’s syndrome), éosinophilie pneumonias (e.g. Loeffler’s syndrome, chronic éosinophilie pneumonia), éosinophilie fasciitis (e.g. Shulman's syndrome), delayed-type hypersensîtivity, non-allergic asthma, exercise induced bronchoconstrîction; chronic obstructive pulmonary disease (COPD), acute bronchitis, chronic bronchitis, cough, pulmonary emphysema; systemic anaphylaxis or hypersensitivity responses, drug allergies (e. g., to penicillin, cephalosporin), eosinophilia-myaîgia syndrome due to the ingestion of contaminated tryptophane, insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, immune thrombocytopenia (adult ITP, néonatal thrombocytopenia, pédiatrie ITP), immune hemolytic anémia (auto
-2416479
25/64 immune and drug induced), Evans syndrome (platelet and red cell immune cytopaenias), Rh disease of the newborn, Goodpasture’s syndrome (anti-GBM disease), Celiac, autoimmune cardio-myopathy juvénile onset diabètes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g. in transplantation), încluding allograft rejection or graftversus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (încluding T-cell mediated psoriasis) and inflammatory dermatoses such as an dermatitis, eczema, atopie dermatitis, allergie contact dermatitis, urticaria; vasculîtis (e.g. necrotizing, cutaneous, and hypersensitivity vasculîtis); erythema nodosum; éosinophilie myositis, éosinophilie fasciitis; cancers with leukocyte infiltration of the skin or organs.
COMBINATIONS
The compounds of formula (la) or (Ib) according to the présent invention may be used on their own or in combination with other compounds of formula (la) or (Ib). The compounds of formula (la) or (Ib) may optionally also be combined with other pharmacologically active substances.
Such pharmacologically active substances useable in the pharmaceutical composition containing compounds of formula (la) or (Ib) of the présent invention may be selected from but are not limited to the classes consisting of ft2-adrenoceptor-agonists (short and longacting beta mimetics), anti-cholinergics (short and long-acting), anti-inflammatory steroids (oral and topical corticosteroids), dïssociated-glucocorticoidmimetics, PDE3 inhibitors, PDE4 inhibitors, PDE7 inhibitors, LTD4 antagonists, EGFR inhibitors, PAF antagonists, Lipoxin A4 dérivatives, FPRL1 modulators, LTB4-receptor (BLT1, BLT2) antagonists, histamine-receptor antagonists, PI3-kinase inhibitors, inhibitors of non-receptor tyrosine kinases as for example LYN, LCK, SYK, ZAP-70, FYN, BTK or ITK, inhibitors of MAP kinases as for example p38, ERK1, ERK2, JNK1, JNK2, JNK3 or SAP, inhibitors of the NF-κΒ signaling pathway as for example IKK2 kinase inhibitors, iNOS inhibitors, MRP4 inhibitors, leukotriene biosynthesis inhibitors as for example 5-Lipoxygenase (5-LO) inhibitors, cPLA2 inhibitors, Leukotriene A4 hydrolase inhibitors or FLAP inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), DP1-receptor modulators, thromboxane receptor antagonists, CCR1 antagonists, CCR2 antagonists, CCR3 antagonists, CCR4 antagonists, CCR5 antagonists, CCR6 antagonists, CCR7 antagonists, CCR8 antagonists, CCR9 antagonists, CCR10 antagonists, CXCR1 antagoniste, CXCR2 antagonists, CXCR3 antagonists, CXCR4 antagonists, CXCR5
-2516479
26/64 antagonists, CXCR6 antagonists, CX3CR1 antagonists, neurokinin (NK1, NK2) antagoniste, sphingosine 1-phosphate receptor modulators, sphingosine 1-phosphate-lyase inhibitors, Adenosine receptor modulators as for example A2a-agonists, modulators of purinergic receptors as for example P2X7 inhibitors, Histone Deacetylase (HDAC) activators, Bradykinin (BK1, BK2) antagonists, TACE inhibitors, PPAR gamma modulators, Rho-kinase inhibitors, interleukin 1-beta converting enzyme (ICE) inhibitors, Toll-like receptor (TLR) modulators, HMG-CoA reductase inhibitors, VLA-4 antagonists, ICAM-1 inhibitors, SHIP agonists, GABAa receptor antagonist, ENaC-inhibitors, Melanocortin receptor (MC1 R, MC2R, MC3R, MC4R, MC5R) modulators, CGRP antagonists, Endothelin antagonists, mucoregulators, immunotherapeutic agents, compounds against swelling of the airways, compounds against cough, CB2 agonists, retinoids, immunosuppressants, mast cell stabilizers, methylxanthine, opioid receptor agonists, laxatives, anti-foaming agents, antispasmodic agents, 5-HT4 agonists but also combinations of two or three active substances.
Preferred are combinations of two or three active substances, i.e.: CRTH2 antagonists according to the présent invention with betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, CCR3 antagonists, CCR5 antagonists, CCR9 antagonists, 5-LO inhibitors, histamine receptor antagonists, SYK inhibitors and sulfonamides, or i.e.:
• CRTH2 antagonists with betamimetics and corticosteroids, PDE4 inhibitors, CCR3 antagonists or LTD4 antagonists, • CRTH2 antagonists with anticholinergics and betamimetics, corticosteroids, PDE4 inhibitors, CCR3 antagonists or LTD4 antagonists, • CRTH2 antagonists with corticosteroids and PDE4 inhibitors, CCR3 antagonists or LTD4 antagonists • CRTH2 antagonists with PDE4 inhibitors and CCR3 antagonists or LTD4 antagonists
In the pharmaceutical compositions according to the présent invention the CRTH2 antagonists of formula (la) or (Ib) may be contained in a form selected from tautomers, optical isomers, enantiomers, racemates, dîastereomers, pharmacologically acceptable acid addition salts, solvatés or hydrates, as far as such forms exist, depending on the individual compound. Pharmaceutical compositions comprising one or more, preferably one, compound 1 in form of a substantially pure enantiomer are preferred.
-26i
27/64
In the pharmaceutical compositions according to the présent invention more than one CRTH2 antagonist of formula (la) or (Ib) and more than one further pharmacologîcally active compound can be présent.
PHARMACEUTICAL FORMS
Suitable préparations for administering the compounds of formula (la) or (Ib) include for example tablets, capsules, suppositories, solutions and powders etc. The content of the pharmaceutically active compound(s) should be in the range from 0.05 to 90 wt.-%, preferably 0.1 to 50 wt.-% of the composition as a whole.
Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gélatine, lubricants such as magnésium stéarate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arable, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or élixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavor enhancer, e.g. a flavoring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions are prepared in the usual way, e.g. with the addition of isotonie agents, preservatives such as p-hydroxybenzoates or stabilizers such as alkali métal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and/or dispersants, while if%</
-27t
28/64 water is used as diluent, for example, organic solvents may optionally be used as solubilisers or dissolving aids, and the solutions may be transferred into injection vials or ampoules or infusion bottles.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gélatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this io purpose, such as neutral fats or polyethyleneglycol or the dérivatives thereof.
Excipients which may be used include but are not limited to water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. éthanol or glycerol), carriers 15 such as e.g. natural minera! powders (e.g. kaolins, clays, talc, chalk), synthetic minerai powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnésium stéarate, talc, stearic acid and sodium lauryl sulphate).
For oral use the tablets may obviously contain, in addition to the carriers specified, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additional substances such as starch, preferably potato starch, gélatine and the like.
Lubricants such as magnésium stéarate, sodium laurylsulphate and talc may also be used to 25 produce the tablets. In the case of aqueous suspensions the active substances may be combined with various flavor enhancers or colorings in addition to the abovementioned excipients.
The compounds of formula (la) or (lb) may also be administered as préparations or
3o pharmaceutical formulations suitable for inhalation. Inhalable préparations include inhalable powders, propellant-containing metered-dose aérosols or propellant-free inhalable solutions. Within the scope of the présent invention, the term propellant-free inhalable solutions also include concentrâtes or stérile inhalable solutions ready for use. The formulations which may be used within the scope of the présent invention are described in more detail in the next part 35 of the spécification.
-2816479
29/64
The inhalable powders which may be used according to the invention may contain (la) or (Ib) either on its own or in admixture with suitable physiologically acceptable excipients.
If the active substances (la) or (Ib) are présent in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to préparé these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium io carbonate) or mixtures of these excipients. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
Within the scope of the inhalable powders according to the présent invention the excipients hâve a maximum average particle size of up to 250 pm, preferably between 10 and 150 pm, most preferably between 15 and 80 pm. It may sometimes seem appropriate to add finer excipient fractions with an average particle size of 1 to 9 pm to the excipient mentioned above. These finer excipients are also selected from the group of possible excipients listed
2o hereinbefore. Finally, in order to préparé the inhalable powders according to the invention, micronised active substance 1, preferably with an average particle size of 0.5 to 10 pm, more preferably from 1 to 5 pm, is added to the excipient mixture. Processes for producing the inhalable powders according to the invention by grinding and micronising and finally mixing the ingrédients together are known from the prior art.
The inhalable powders according to the invention may be administered using inhalers known from the prior art.
The inhalation aérosols containing propellant gas according to the invention may contain the 30 compounds of formula (la) or (Ib) dissolved in the propellant gas or in dispersed form. The compounds of formula (la) or (Ib) may be contained in separate formulations or in a common formulation, in which the compounds of formula (la) or (Ib) are either both dissolved, both dispersed or in each case only one component is dissolved and the other is dispersed. The propellant gases which may be used to préparé the inhalation aérosols are known from the 35 prior art. Suitable propellant gases are selected from among hydrocarbons such as/l·'’—''
-2916479
30/64 n-propane, π-butane or isobutane and halohydrocarbons such as fluorinated dérivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The abovementioned propellant gases may be used on their own or mixed together. Particularly preferred propellant gases are halogenated alkane dérivatives selected from TG134a and TG227 and 5 mixtures thereof.
The propellant-driven inhalation aérosols may also contain other ingrédients such as co-solvents, stabilizers, surfactants, antioxidants, lubricants and pH adjusters. Ail these ingrédients are known in the art.
The propellant-driven inhalation aérosols according to the invention mentioned above may be administered using inhalers known in the art (MDIs = metered dose inhalers).
Moreover, the active substances of formula (la) or (Ib) according to the invention may be administered in the form of propellant-free inhalable solutions and suspensions. The solvent used may be an aqueous or alcoholic, preferably an ethanolic solution. The solvent may be water on its own or a mixture of water and éthanol. The relative proportion of éthanol compared with water is not limited but the maximum is preferably up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume. The remainder of the volume is made up of water. The solutions or suspensions containing compounds of formula (la) or (Ib) are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from înorganic or organic acids. Examples of particularly suitable înorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid. Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred înorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which hâve already formed an acid addition sait with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may be used, particularly in the case of acids which hâve other properties in addition to their acidifying qualities, e.g. as flavorings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH. ----3016479
31/64
If desired, the addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as stabilizer or complexing agent may be omitted in these formulations. Other embodiments may contain this compound or these compounds. In a preferred embodiment the content based on sodium edetate is less than 100 mg/100 ml, preferably less than
50mg/100ml, more preferably less than 20 mg/100 ml. Generally, inhalable solutions in which the content of sodium edetate is from 0 to 10 mg/100 ml are preferred.
Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions. Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g.
alcohols - particularly isopropyl alcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. The terms excipients and additives in this context dénoté any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the physiologically suitable solvent in order to improve the qualitative properties of the active substance formulation. Preferably, these substances hâve no pharmacological effect or, in connection with the desired therapy, no appréciable or at least no undesirable pharmacological effect. The excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilizers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavorings, vitamins and/or other additives known in the art. The additives also include pharmacologically acceptable salts such as sodium chloride as isotonie agents.
The preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.
Preservatives may be used to protect the formulation from contamination with pathogens.
Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art. The preservatives mentîoned above are preferably présent in concentrations of up to 50 mg/100 ml, more preferably between 5 and mg/100 ml.
-31·.
32/64
The dosage of the compounds according to the invention is naturally highfy dépendent on the method of administration and the complaint which is being treated. When adminîstered by inhalation the compounds of formula (la) or (lb) are characterized by a high potency even at doses in the pg range. The compounds of formula (la) or (lb) may also be used effectively above the pg range. The dosage may then be in the gram range, for example.
In another aspect the présent invention relates to the above-mentioned pharmaceutical formulations as such which are characterized in that they contain a compound of formula (la) or (lb), particularly the above-mentioned pharmaceutical formulations which can be adminîstered by inhalation.
The following examples of formulations illustrate the présent invention without restricting its scope:
Examples of pharmaceutical formulations:
A) Tablets per tablet active substance (la) or (lb) 100 mg lactose 140 mg maize starch 240 mg polyvinylpyrrolidone 15mg magnésium stéarate 5 mg
500 mg
The finely ground active substance, lactose and some of the maize starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet granulated and dried. The granules, the remaining maize starch and the magnésium stéarate are screened and mixed together. The mixture is pressed into tablets of suitable shape and size.
B) Tablets per tablet active substance (la) or (lb) 80 mg lactose 55 mg maize starch
-3216479
33/64
microcrystalline cellulose polyvinylpyrrolidone sodium carboxymethyl starch magnésium stéarate | 35 mg 15 mg 23 mg 2 mg |
Σ | 400 mg |
The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium carboxymethyl starch and the magnésium stéarate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
C) Ampoule solution
active substance (la) or (lb) sodium chloride | 50 mg 50 mg |
water for inj. | 5 ml |
The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make the solution isotonie. The resulting solution is filtered to remove pyrogens and the filtrate is transferred under aseptie conditions into ampoules which are then sterilized and heat-sealed. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.
D) Metering aérosol active substance (la) or (lb) sorbitan trioleate monofluorotrichloromethane and | 0.005 0.1 |
TG134a:TG227 2:1 | ad 100 |
The suspension is transferred into a conventional aérosol container with metering valve. Preferably 50 μΙ suspension are released on each actuation. The active substance may also be released in higher doses if desired (e.g. 0.02 wt.-%).
-33P01-2691-ff
34/64
E) Solutions (in mg/100ml) active substance (la) or (Ib) benzalkonium chloride | 333.3 mg 10.0 mg |
EDTA | 50.0 mg |
HCl (1N) | ad pH 2.4 |
This solution can be prepared in the usual way.
F) Inhalable powder active substance (la) or (Ib) 12 pg lactose monohydrate ad 25 mg
The inhalable powder is prepared in the usual way by mixing the individual ingrédients.
The following examples serve to further illustrate the présent invention without restrîcting its scope.
EXAMPLES
I. HPLC METHODS
Method A:
HPLC-MS: AgilentHOO
Mobile phase:
A: water with 0.032% NH4OH
B: methanol | |||
time in min | %A | %B | flow rate in ml/min |
0.00 | 95 | 5 | 1.50 |
2.00 | 0 | 100 | 1.50 |
2.50 | 0 | 100 | 1.50 |
2.60 | 95 | 5 | 1.50 |
2.90 | 95 | 5 | 1.50 |
Column: XBridge C18, 3,5pm, 4,6 x 50mm (column température: constant at 40°C).
Détection by diode array detector at 210-500 nm wavelength.
-3416479
35/64
Method B:
HPLC-MS: Waters ZQ MS, Alliance 2690/2695 HPLC, 2996 diode array detector
Mobile Phase:
A: water with 0.1% TFA
B: methanoi
time in min | %A | %B | flow rate in ml/min |
0.00 | 95 | 5 | 4.0 |
0.20 | 95 | 5 | 4.0 |
1.60 | 0 | 100 | 4.0 |
2.10 | 0 | 100 | 4.0 |
Column: Waters XBridge C18, 4.6 x 20 mm, 3.5 pm (column température: constant at 40°C). Détection by diode array detector at 210-400 nm wavelength.
Method C:
HPLC: Waters Acquity with DA and MS detector
Mobile Phase:
A: water with 0.1% TFA
B: methanoi
time in min | %A | %B | flow rate in ml/min |
0.00 | 99 | 1 | 1.5 |
0.05 | 99 | 1 | 1.5 |
1.05 | 0 | 100 | 1.5 |
1.20 | 0 | 100 | 1.5 |
Column: Waters XBridge BEH C18, 2.1 x 30 mm, 1.7 pm (column température: constant at 60°C). Détection by diode array detector at 210-400 nm wavelength.
Method D:
HPLC: Waters Acquity with DA and MS detector
Mobile Phase:
A: water with 0.13% TFA
B: methanoi with 0.05% TFA
time in min | %A | %B | flow rate in ml/min |
0.00 | 99 | 1 | 1.3 |
0.05 | 99 | 1 | 1.3 |
-3516479
36/64
1.05 0 100 1.3
1.20 0 100 1.3
Column: Waters XBridge BEH C18, 2.1 x 30 mm, 1.7 pm (column température: constant at 60°C). Détection by diode array detector at 210-400 nm wavelength.
Method E:
HPLC: Waters Acquity with DA and MS detector
Mobile Phase:
A: water with 0.1% TFA
B: methanol
time in min | %A | %B | flow rate in ml/min |
0.00 | 95 | 5 | 1.4 |
0.05 | 95 | 5 | 1.4 |
1.00 | 0 | 100 | 1.4 |
1.10 | 0 | 100 | 1.4 |
Column: Waters XBridge C18, 2.1 x 30 mm, 2.5 pm (column température: constant at 60°C). Détection by diode array detector at 210-400 nm wavelength.
Method F:
HPLC: Agilent 1200 with DA and MS detector
Mobile Phase:
A: water with 0.1 % TFA
B: methanol
time in min | %A | %B | flow rate in ml/min |
0.00 | 95 | 5 | 2.0 |
0.20 | 95 | 5 | 2.0 |
1.50 | 0 | 100 | 2.0 |
1.55 | 0 | 100 | 2.6 |
1.75 | 0 | 100 | 2.6 |
Column: Waters XBridge C18, 3 x 30 mm, 2.5 pm (column température: constant at 60°C).
Détection by diode array detector at 210-400 nm wavelength.
Method G:
HPLC-MS: Waters Alliance with DA and MS detector
Mobile Phase:
-3616479
37/64
A: water with 0.1% NH3
B: methanol with 0.1% NH3
time in min | %A | %B | flow rate in ml/min |
0.00 | 95 | 5 | 4.0 |
0.20 | 95 | 5 | 4.0 |
1.50 | 0 | 100 | 4.0 |
1.75 | 0 | 100 | 4.0 |
Column: Waters XBridge C18, 4.6 x 30 mm, 3.5 pm (column température: constant at 60°C). Détection by diode array detector at 210-400 nm wavelength.
Method H:
HPLC-MS: Waters Alliance with DA and MS detector
Mobile Phase:
A: water with 0.1% TFA
B: methanol
time in min | %A | %B | flow rate in ml/min |
0.00 | 95 | 5 | 4.8 |
1.60 | 0 | 100 | 4.8 |
1.85 | 0 | 100 | 4.8 |
1.90 | 95 | 5 | 4.8 |
Column: Waters SunFire C18, 4.6 x 30 mm, 3.5 pm (column température: constant at 60°C).
Détection by diode array detector at 210-400 nm wavelength.
Method J:
HPLC: Waters Acquity with DA and MS detector
Mobile Phase:
A: water with 0.13 % TFA
B: methanol with 0.05 % TFA
time in min | %A | %B | flow rate in ml/min |
0.00 | 99 | 1 | 1.2 |
0.15 | 99 | 1 | 1.2 |
1.10 | 0 | 100 | 1.2 |
1.25 | 0 | 100 | 1.2 |
Column: Waters Sunfire C18, 2.1 x 30 mm, 2.5 pm (column température: constant at 60°C).
Détection by diode array detector at 210-400 nm wavelength. U/—
-3716479
38/64
Method K:
HPLC-MS: Waters Alliance with DA and MS detector
Mobile Phase:
A: water with 0.1% TFA
B: methanol with 0.1% TFA
time in min | %A | %B | flow rate in ml/min |
0.00 | 95 | 5 | 4.0 |
0.20 | 95 | 5 | 4.0 |
1.50 | 0 | 100 | 4.0 |
1.75 | 0 | 100 | 4.0 |
1.85 | 95 | 5 | 4.0 |
Column: Waters XBridge C18, 4.6 x 30 mm, 3.5 pm (column température: constant at 60°C). Détection by diode array detector at 210-400 nm wavelength.
Method L:
HPLC-MS: Waters Alliance with DA and MS detector
Mobile Phase:
A: water with 0.1% TFA
B: methanol
time in min | %A | %B | flow rate in ml/min |
0.00 | 95 | 5 | 4.8 |
1.60 | 0 | 100 | 4.8 |
1.85 | 0 | 100 | 4.8 |
1.90 | 95 | 5 | 4.8 |
Column: Waters XBridge C18, 4.6 x 30 mm, 3.5 pm (column température: constant at 60°C). Détection by diode array detector at 210-400 nm wavelength.
Method M:
HPLC-MS: Waters 2695 HPLC, ZQ MS, 2996 diode array detector, 2695 autosampler
Mobile Phase:
A: water with 0.1% NH3
B: methanol with 0.1% NH3 time in min %A %B flow rate in ml/min
0.00 95 5 4.0
-3816479
39/64
0.20 | 95 | 5 | 4.0 |
1.50 | 0 | 100 | 4.0 |
1.75 | 0 | 100 | 4.0 |
Column: Waters XBridge C18, 4.6 x 30 mm, 3.5 pm (column température: constant at 60°C). Détection by diode array detector at 210-400 nm wavelength.
Method N:
HPLC: Waters Acquity with DA and MS detector
Mobile Phase:
A: water with 0.13% TFA
B: methanol with 0.08% TFA
time in min | %A | %B | flow rate in ml/min |
0.00 | 99 | 1 | 1.3 |
0.05 | 99 | 1 | 1.3 |
0.35 | 0 | 100 | 1.3 |
0.50 | 0 | 100 | 1.3 |
Column: Waters XBridge BEH C18, 2.1 x 30 mm, 1.7 pm (column température: constant at 60°C). Détection by diode array detector at 210-400 nm wavelength.
Method O:
HPLC: Agilent 1200 with DA and MS detector
Mobile Phase:
A: water with 0.1 % TFA
B: methanol
time in min | %A | %B | flow rate in ml/min |
0.00 | 95 | 5 | 1.9 |
0.20 | 95 | 5 | 1.9 |
1.55 | 0 | 100 | 1.9 |
1.60 | 0 | 100 | 2.4 |
1.80 | 0 | 100 | 2.4 |
Column: Waters XBridge C18, 3 x 30 mm, 2.5 pm (column température: constant at 60°C). Détection by diode array detector at 210-400 nm wavelength.
II. SYNTHESIS OF STARTING COMPOUNDS
-3916479
40/64
A) Synthesis of Amines
1. ) [1-(4-Aminobenzyl)-3,5-djmethyl-1H-pyrazol-4-yl]acetic acid methyi ester
a) To a solution of (3.5-dimethyl-1H-pyrazol-4-yl)-acetic acid methyl ester (3.90 g, 23 mmol) and 4-nitrobenzyl bromide (4.60 g, 20.7 mmol) in acetonitrile is added K2CO3 (2.76 g, 19.9 mmol) and the mixture is stirred for one hour at room température. The reaction mixture is poured into water and extracted twice with ethyl acetate. The organic phase is dried over MgSO4 and evaporated under reduced pressure. To yield 7.50 g of [3,5-Dimethyl-1 -(4-nitrobenzyl)-1H-pyrazol-4-yl]-aceticacid methyl ester (ESl mass spectrum: [M+H]* = 304).
b) To a solution of [3,5-dimethyl-1-(4-nitro-benzyl)-1H-pyrazol-4-yl]-acetic acid methyl ester (3.90 g, 10.3 mmol) in methanol (10 mL) is added 10 % palladium on charcoal (500 mg) and the mixture is hydrogenated. The catalyst is filtered off and the filtrate is concentrated under reduced pressure. The mixture is purified via préparative reversed phase HPLC (gradient of methanol in water + 0.1 % NH3) to yield 1.18 g of the title compound (ESl mass spectrum: [M+H]* = 274; Rétention time HPLC: 2.13 min (method A))
2. ) [1-(4-Amino-2-chloro-benzyl)-3,5-dimethyl-1H-pyrazol-4-yl]acetic acid ethyl ester
a) To a solution of (3,5-dimethyl-1H-pyrazol-4-yl)-acetic acid ethyl ester (1.40 g, 7.7 mmol) and 2-chloro-4-nitrobenzyl bromide (4.60 g, 20.7 mmol) in 20 mL acetonitrile is added K2CO3 (1.59 g, 11.5 mmol) and the mixture is stirred for 48 hours at room température. The solvent is removed by évaporation and the residue is dissolved in dichloromethane/water. After extraction with dichloromethane the organic layer is dried over Na2SO4 and evaporated under reduced pressure to yield 2.79 g of [3,5-dimethyl-1-(2-chloro-4-nitro-benzyl)-1H-pyrazol-4-yl]acetic acid ethyl ester (ESl mass spectrum: [M+H]* = 352; Rétention time: 1.95 min (method A).
b) To a solution [3,5-dimethyl-1-(2-chloro-4-nitro-benzyl)-1H-pyrazol-4-yl]acetic acid ethyl ester (2.39 g, 6.8 mmol) in methanol (40 mL) is added Raney nickel (250 mg) and the mixture is hydrogenated. The catalyst is filtered off and the filtrate is concentrated under ycs'
-4016479
41/64 reduced pressure to yield 1,18 g of the title compound (ESI mass spectrum: [M+Hf = 322;
Rétention time HPLC: 1.76 min (method A)).
3. ) [1-(4-Amino-benzyl)-3,5-diethyl-1H-pyrazol-4-yl]-acetic acid ethyl ester
a) To a solution of (3,5-diethyl-1H-pyrazol-4-yl)-acetic acid ethyl ester (10.95 g, 52.1 mmol) and 4-nitrobenzyl bromide (14.625 g, 68 mmol) in acetonitrile (110 mL) is added K2CO3 (10.80 g, 78.1 mmol) and the mixture is stirred for 48 hours at room température. The reaction mixture is poured into water and extracted twice with ethyl acetate. The organic phase is dried over MgSO4 and evaporated under reduced pressure. The residue is purified by MPLC with ethyl acetate/cyclohexane to yield 12.50 g [3,5-diethyl-1-(4-nitro-benzyl)-1Hpyrazol-4-yl]acetic acid ethyl ester (ESI mass spectrum: [M+H]+ = 346; Rétention time HPLC: 1.42 min (method B)).
b) To a solution of [3,5-diethyl-1-(4-nitro-benzyl)-1H-pyrazol-4-yl]acetic acid ethyl ester (6.66 g, 19.3 mmol) in methanol (500 mL) is added Raney nickel (500 mg) and the mixture is hydrogenated at 50 psi and room température. The catalyst is filtered off and the filtrate is concentrated under reduced pressure to yield 4.38 g of the title compound (ESI mass spectrum: [M+H]+ = 316; Rétention time HPLC: 1.09 min (method B)).
4. ) [1-(4“Amino-2-fluorobenzyl)“3,5-dimethyl-1H-pyrazol-4-yl]acetic acid methyl ester
a) To a solution of (3,5-dimethyl-1 H-pyrazol-4-yl)-acetic acid methyl ester (10 g, 48.9 mmol) and 2-fluoro-4-nitrobenzyl bromide (11.5 g, 49.1 mmol) in acetonitrile (150 mL) is added K2CO3 (10.1 g, 73.3 mmol) and the mixture is stirred for 48 hours at 60°C. The solvent is removed by évaporation and the residue is dissolved in dichloromethane/water. After extraction with dichloromethane the organic layer is dried over Na2SO4 and evaporated under reduced pressure. The residue is purified by MPLC (cyclohexane/diethyl ether 7:3) to yield 13 g of [3,5-dimethyl-1-(2-fluoro-4-nitro-benzyl)-1H-pyrazol-4-yl]acetic acid methyl ester (ESI mass spectrum: [M+Hf = 322; Rétention time (HPLC): 0.85 min (method C)).
b) To a solution of [3,5-dimethyl-1-(2-fluoro-4-nitro-benzyl)-1H-pyrazol-4-yl]acetic acid methyl ester (13 g, 40.4 mmol) in methanol (250 mL) is added Raney nickel (6 g) and the mixture is ,
-4116479
42/64 hydrogenated at 50 psi and 50°C. The catalyst is filtered off and the filtrate is concentrated under reduced pressure. The mixture is purified by crystailization in diisopropyl ether to yield 12.8 g of the title compound (ESl mass spectrum: [M+H]+ = 292; Rétention time HPLC: 0.61 min (method C)).
5. ) [1-(4-Amino-2-chloro-benzyl)-3,5-dimethyl-1H-pyrazol-4-yl]-acetic acid tert-butyl ester
a) To a solution of (3,5-dimethyl-1H-pyrazol-4-yl)-acetic acid tert-butyl ester (2.6 g, 12.4 mmol, préparation according to WO2007/141267 by using 2,4-pentanedione instead of 3,5heptanedione) and 2-chloro-4-nitrobenzyl bromide (3.11 g, 12.4 mmol) in acetonitrile (30 mL) is added K2CO3 (2.575 g, 18.6 mmol) and the mixture is stirred for 48 hours at room température and after that 2 hours at 60°C. The solid is filtered off and the solvent is removed by évaporation. The residue is dissolved in dichloromethane/water. After extraction with dichloromethane the organic layer is dried over MgSO4 and evaporated under reduced pressure to yield 4.4 g of [3,5-dimethyl-1-(2-chloro-4-nitrobenzyl)-1 H-pyrazol-4-yl]acetic acid tert-butyl ester (ESI mass spectrum: [M+H]+ = 380).
b) To a solution of [3,5-dimethyl-1-(2-chloro-4-nitrobenzyl)-1H-pyrazol-4-yl]acetic acid tertbutyl ester (4.40 g, 11.6 mmol) in methanol (80 mL) is added Raney nickel (440 mg) and the mixture is hydrogenated at 50 psi and room température for 12 hours. The catalyst is filtered off and the filtrate is concentrated under reduced pressure to yield 2.4 g of the title compound (ESl mass spectrum: [M+H]+ = 350; Rétention time HPLC: 0.76 min (method D)).
6. ) [1-(4-Aminobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl]acetic acid tert-butyl ester
The title compound (ESl mass spectrum: [M+H]+ = 316; Rétention time HPLC: 0.65 min (method E)) is synthesized in analogy to procedure II.A.5 by using 4-nitrobenzylbromide instead of 2-fluoro-4-nitrobenzylbromide.
7. ) [1-(4-Amino-2-fluorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl]acetic acid tert-butyl ester
a) To a solution of (3,5-dimethyl-1 H-pyrazol-4-yl)acetic acid tert-butyl ester (10 g, 47.6 mmol, préparation according to WO2007/141267 by using 2,4-pentanedione instead of 3,5
-4216479
43/64 heptanedione) and 2-fluoro-4-nitrobenzyl bromide (11.2 g, 47.9 mmol) in acetonitrile (150 mL) is added K2CO3 (6.615 g, 47.9 mmol) and the mixture is stirred for 24 hours at room température. The solid is filtered off and the solvent is removed by évaporation. The residue is dissolved in dichloromethane/water. After extraction with dichloromethane the organic layer is dried over MgSO4 and evaporated under reduced pressure. The residue is purified by MPLC (cyclohexane/ethyl acetate 7:3, silicagel 60) to yield 13.6 g of [3,5-dimethyl-1-(2fluoro-4-nitrobenzyl)-1H-pyrazol-4-yl]acetic acid tert-butyl ester (ESl mass spectrum: [M+H]+ = 364 TLC: Rf = 0.23 (cyclohexan/ethyl acetate 7:3, solicagel 60 F254)).
b) To a solution of [3,5-dimethyl-1-(2-fluoro-4-nitrobenzyl)-1H-pyrazol-4-yl]acetic acid tertbutyl ester (13.6 g, 37.4 mmol) in methanol (250 mL) is added Raney nickel (6 g) and the mixture is hydrogenated at 50 psi and 50°C for 12 hours. The catalyst is filtered off and the filtrate is concentrated under reduced pressure to yield 11.6 g of the tiltle compound (ESl mass spectrum: [M+Hf = 334; TLC: Rf = 0.53 (dichloromethane/methanol 95:5, silicagel 60 F254)).
B) Synthesis of carboxylic acids
1.) 1-Ethyl-5-fluoro-1H-indole-2-carboxylic acid
a) To a solution of 5-fluoroindol-2-ethyl ester (200 mg, 0.965 mmol) in dimethylsulfoxide (6 mL) is added potassium tert-butylate (108 mg, 0.965 mmol) and the mixture is stirred at 50°C for 30 minutes. After cooling to room température bromoethane (0.081 mL, 1.06 mmol) is added and the mixture is stirred at room température for 2.5 hours. With cooling water is added and the mixture is extracted with ethyl acetate. The organic layer is washed with water and saturated aqueous NaCI solution, dried over MgSO4 and the solvent is evaporated in vacuo to yield 200 mg of 1-ethyl-5-fluoro-1H-indole-2-carboxylic acid ethyl ether (ESl mass spectrum: [M+Hf = 236).
b) To a solution of 1-ethyl-5-fluoro-1 H-indole-2-carboxylic acid ethyl ether (200 mg, 0.85 mmol) in dioxan (2 mL) is added an aqueous solution of NaOH (1 M, 1.7 mL) and the mixture is stirred at 60°C for 1 hour. After évaporation of the solvent the residue was suspended in a few water and neutralized with acetic acid (2 M). The precipitate is filtered, washed with
-4316479
44/64 water and dried to yield 140 mg of the title compound (ESI mass spectrum: [M+H]’ = 208;
Rétention time HPLC: 1.21 min (method F)).
The following indole carboxylic acids are prepared likewise in anlaogy to this method:
1-Benzyl-1H-indole-2-carboxylic acid (ESI mass spectrum: [M+H]* = 252 Rétention time HPLC: 0.84 min (method E));
1-Butyl-1H-indole-2-carboxylic acid (ESI mass spectrum: [M+H]* = 218);
5- Fluoro-1-propyl-1H-indole-2-carboxylic acid (ESI mass spectrum: [M+H]’= 222);
1-Butyl-5-fluoro-1H-indole-2-carboxylic acid (ESI mass spectrum: [M+H]+ = 236);
1-Propyl-1H-indole-2-carboxylic acid (ESI mass spectrum: [M+H]* = 204);
1-Ethyl-4-fluoro-1H-indole-2-carboxylîcacid (ESI mass spectrum: [M+H]* = 208; Rétention time HPLC: 0.80 min (method E);
1-Ethyl-6-fluoro-1H-indole-2-carboxylîc acid (ESI mass spectrum: [M+H]'=206; Rétention time HPLC: 0.71 min (method E));
6- Fluoro-1-propyl-1H-indole-2-carboxylic acid (ESI mass spectrum: [M-H] = 220; Rétention time HPLC: 0.77 min (method E)).
2.) 3-Ethyl-5-fluorobenzofuran-2-carboxylic acid
a) To a solution of 5-fluoro-2-hydroxy-propiophenone (0.9 g, 5.2 mmol) and tert-butyl bromoacetate (0.9 mL, 6.1 mmol) in acetonitrile (15 mL) is added K2CO3 (1.08 g, 7.8 mmol) and the mixture is refluxed for 3 hours. After cooling to room température the mixture is poured into water and extracted with ethyl acetate. The organic layer is washed twice with water, dried over MgSO4 and the solvent is evaporated in vacuo to yield 1.47 g of (4-fluoro-2propionylphenoxy)acetic acid tert-butyl ester (ESI mass spectrum: [M+H]* = 283; Rétention time HPLC: 0.88 min (method D)). v/*
-4416479
45/64
b) To a solution of (4-fluoro-2-propionylphenoxy)acetic acid tert-butyl ester (1.47 g, 5.2 mmol) in dry éthanol (20 mL) is added solution of sodium methanolat in methanol (5.4 M, 20 mL) and the mixture is stirred at 80°C for 12 hours. After cooling to room température and évaporation of the solvent the residue was dissolved in water and acidified with hydrochloric acid (1 M). The precipitate is filtered, washed with water and dried to yield 440 mg of the title compound (ESI mass spectrum: [M-H]' = 207; Rétention time HPLC: 0.87 min (method G)).
The following benzofuran carboxylic acids are prepared likewise in analogy to this method:
7-Chloro-3-methylbenzofuran-2-carboxylic acid (ESI mass spectrum: [M-H]' = 209; Rétention time HPLC: 1.28 min (method H));
5- Fluoro-3-propylbenzofuran-2-carboxylic acid (ESI mass spectrum: [M-H]’ = 221; Rétention time HPLC: 1.01 min (method G));
3-Ethyl-7-fluorobenzofuran-2-carboxylic acid (ESI mass spectrum: [M-H]' = 207; Rétention time HPLC: 0.77 min (method E));
3-Ethyl-5,7-difluorobenzofuran-2-carboxylic acid (ES! mass spectrum: [M-H]‘ = 225; Rétention time HPLC: 1.32 min (method L));
6- Chlorobenzofuran-2-carboxylic acid (ESI mass spectrum: [M-H]' = 195; Rétention time HPLC: 1.72 min (method H)).
III) SYNTHESIS OF COMPOUNDS (la) and (Ib)
Compound 1: (1-(2-fluoro-4-[(1H-indole-2-carbonyl)amino]benzyl)-3,5-dimethyl-1H-pyrazol-4yl)acetic acid (Coupling method C1):
a) To a solution of indole-2-carboxylic acid (80 mg, 0.50 mmol) in Ν,Ν-dimethylformamide (1.5 mL) are added TBTU (139 mg, 0.43 mmol) and Ν,Ν-diisopropyl amine (0.126 mL, 0.74 mmol). Subsequently [1-(4-amino-2-fluorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl]acetic acid methyl ester (120 mg, 0.41 mmol) is added. The mixture is stirred at room température for 12
-4516479
46/64 hours. After that an aqueous solution of K2CO3 (2 M, 0.5 mL) is added. The obtained mixture is flushed through AI2O3 with dichloromethane/methanol (9:1, 10 mL). The solvent is removed in vacuo to yield 82.3 mg of (1-(2-fluoro-4-[(1H-indole-2-carbonyl)amino]benzyl)-3,5-dimethyl1 H-pyrazol-4-yl)acetic acid methyl ester (ESl mass spectrum: [M+Hf = 435; Rétention time HPLC: 0.41 min (method N).
b) (1-(2-Fluoro-4-[(1H-indole-2-carbonyl)amino]benzyl)-3,5-dimethyl-1H-pyrazol-4-yl)acetic acid methyl ester (82 mg, 0.19 mmol) is dissolved in methanol (0.5 mL). An aqueous solution of NaOH (4M, 0.3 mL) is added and the mixture is stirred at room température for 2 hours. The resulting mixture is diluted with methanol/water, the solid is filtered off and after évaporation the residue is purified by HPLC (Gilson, XRS Pursuit, methanol/H2O+0.1 % conc. NH3). The fractions containing the title compound are concentrated and lyophilized to yield 15 mg of the title compound (ESl mass spectrum: [M+Hf = 421; Rétention time HPLC: 1.04 min (method G)).
1H-NMR 400 MHz (DMSO-d6): δ [ppm] = 2.03 (s, 3H). 2.14 (s, 3H), 2.52 (s, 3H), 3.21 (s, 2H), 5.16 (s, 2H), 6.99 (t, 1H), 7.08 (t, 1H), 7.23 (t, 1H), 7.39 (s. 1H), 7.48 (m, 2H), 7.66 (d, 1H), 7.79 (d, 1H), 10.45 (s, 1H), 11.79 (br., 1H).
Compounds 2 and 3 of table 1 below hâve likewise been prepared in analogy to coupling method C1 using suitable starting amines and carboxylic acids.
Compound 4: (1 -{4-[(5-Fluoro-3-methylbenzofuran-2-carbonyl)amino]benzyl)-3,5-dimethyl1 H-pyrazol-4-yl)acetic acid (Coupling method C2):
a) To a solution of [1-(4-aminobenzyl)-3,5-dimethyl-1 H-pyrazol-4-yl]acetic acid methyl ester (400 mg, 1.46 mmol) in 5 mL dichloromethane are added diisopropylethylamine (1.5 mL, 8.8 mmol) and 5-fluoro-3-methyl-1-benzofuran-2-carboxylic acid (369 mg, 1.9 mmol). After stirring at room température for 10 minutes a 50 % solution of 1-propylphosphonic acid cyclic anhydride in ethyl acetate (1.725 mL, 2.93 mmol) is added with cooling and the mixture is stirred at room température for 12 hours. The solvent is evaporated in vacuo and the residue is purified by MPLC (dichloromethane/methanol 98:2) to yield 410 mg of (1-{4-[(5-fluoro-3methylbenzofuran-2-carbonyl)amino]benzyl)-3,5-dimethyl-1 H-pyrazol-4-yl)acetic acid methyl ester (ESl mass spectrum: [M+Hf = 450; TLC: Rf = 0.56 (dichloromethane/methanol 95:5, silicagel 60 F254)).
-4616479
47/64
b) To a solution of (1-{4-[(5-fluoro-3-methylbenzofuran-2-carbonyl)amino]benzyl}-3,5dimethyl-1H-pyrazol-4-yl)acetic acid methyl ester (410 mg, 0.91 mmol) in dioxan/water (10 mL/10 mL) is added 1 M NaOH (2.3 mL) and the mixture is stirred at room température for 24 hours. The mixture is diluted with water and acidified with hydrochlorîc acid (1 M, 3.25 mL). The precipitate is filtered, washed with water and dried to yield 338 mg of the title compound (ESI mass spectrum: [M+H]+ = 436; Rétention time HPLC: 0.85 min (method D).
1H-NMR 400 MHz (DMSO-d6): δ [ppm] = 2.05 (s, 3H), 2.10 (s, 3H), 2.52 (s, 3H), 3.24 (s, 2H), 5.16 (s, 2H), 7.10 (d, 2H), 7.37 (t, 1H), 7.66 (m, 2H), 7.75 (d, 2H), 10.40 (s, 1H), 12.05 (br.,
1H).
Compounds 5 to 26 and 57 to 59 of tables 1 and 2 below hâve likewise been prepared in analogy to coupiing method C2 using suitable starting amines and carboxylic acids.
Compound 27: (1 -{2-Fluoro-4-[(5-fluoro-3-methylbenzofuran-2-carbonyl)amino]benzyl}-3,5dimethyl-1H-pyrazol-4-yl)-acetic acid (Coupiing method C3):
a) To a solution of 5-fluoro-3-methyl-1-benzofuran-2-carboxylicacid (194 mg, 1 mmol) in 5 mL dimethylformamide is added diisopropylethylamine (0.516 mL, 3 mmol) and HATU (399 mg, 1.05 mmol) is added. After stirring at room température for 25 minutes dimethylformamide (1 mL) and then intermediate [1-(4-amino-2-fluorobenzyl)-3,5-dimethyl1 H-pyrazol-4-yl]acetic acid methyl ester (291 mg, 1 mmol) is added. Subsequently diisopropylethylamine (0.344 mL, 2 mmol) and dimethylformamide (2 mL) is added, and the mixture is stirred at room température for 48 hours. Then ethyl actetate and water are added and the precipitate is filtered off. The organic layer is extracted twice with acetic acid (1 N), once with an aqueous solution of NaHCO3 (5 % by weight) and twice with water, dried over MgSO4. The solvent is removed by évaporation in vacuo. The residue is prurified by MPLC (dichloromethane/methanol 96:4) to yield 120 mg of (1-(2-fluoro-4-[(5-fluoro-3methylbenzofuran-2-carbonyl)-amino]-benzyl)-3I5-dimethyl-1H-pyrazol-4-yl)-acetic acid methyl ester (ESI mass spectrum: [M+H]+ = 468; TLC: Rf = 0.72 (dichloromethane/methanol 9:1, silicagel 60 F254)).
b) To a solution of (1-(2-fluoro-4-[(5-fluoro-3-methylbenzofuran-2-carbonyl)-amino]-benzyl)-
3,5-dimethyl-1 H-pyrazol-4-yl)-acetic acid methyl ester (119 mg, 0.26 mmol) in dioxan/water
-4716479
48/64 (7 mL/7 mL) is added an aqueous solution of NaOH (1 M, 2.3 mL) and the mixture is stirred at room température for 12 hours and at 60°C for 2 hours. The mixture is diluted with water, acidified with hydrochloric acid (1 M, 1 mL) and extracted with ethyl acetate. The organic layer is dried over MgSO41 the solvent evaporated in vacuo, the residue is crystallized with diisopropylether and the precipitate is isolated by filtration to yield 69 mg of the title compound (ESI mass spectrum: [M+Hf = 454; Rétention time HPLC: 0.90 min (method D)).
1H-NMR 400 MHz (DMSO-d6): δ [ppm] = 2.03 (s, 3H), 2.14 (s, 3H), 2.57 (s, 3H), 3.28 (s, 2H), 5.18 (s, 2H), 6.96 (t, 1H), 7.37 (t, 1H), 7.54 (d, 1H), 7.66 (m, 2H), 7.79 (d, 1H), 10.60 (s, 1H), 12.07 (br., 1H).
Compounds 28 to 31 of table 1 below hâve likewise been prepared in analogy to coupling method C3 using suitable starting amines and carboxylic acids.
Compounds 32: (1-(4-[(1-Ethyl-5-fluoro-1H-indole-2-carbonyl)amino]-2-fluorobenzyl)-3,5dimethyl-1H-pyrazol-4-yl)acetic acid (Coupling method C4):
a) To a solution of 1-ethyl-5-fluoro-1H-indole-2-carboxylic acid (140 mg, 0.68 mmol) in 6 mL dichloromethane is added oxalyl chloride (0.094 mL, 0.68 mmol) and a drop dimethylformamide. After stirring at room température for 1 hour the solvent is removed by évaporation in vacuo. The residue is dissolved in dichloromethane (5 mL) and dropped to a solution of [1-(4-amino-2-fluorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl]acetic acid methyl ester (177 mg, 0.61 mmol) and diisopropylethylamine (0.23 mL, 1.35 mmol) in dichloromethane (5 mL). After addition of 4-dimethylaminopyridine (8.255 mg, 0.069 mmol) the solution is stirred at room température for 12 hours. The solution is extracted twice with hydrchloric acid (1 M), twice with water, twice with an aqueous solution of NaOH (1 M) and twice with water. The organic layer is dried over MgSO4, filtered and the solvent is evaporated in vacuo. The residue is purified by MPLC (dichloromethane/methanol 95:5) to yield 160 mg of (1-(4-[(1ethyl-5-fluoro-1H-indole-2-carbonyl)amino]-2-fluorobenzyl)-3,5-dimethyl-1H-pyrazol-4yl)acetic acid methyl ester (ESI mass spectrum: [M+H]+ = 481; Rétention time HPLC: 0.93 min (method D)).
b) To a solution of (1-(4-[(1-ethyl-5-fluoro-1H-indole-2-carbonyl)amino]-2-fluorobenzyl)-3,5dimethyl-1H-pyrazol-4-yl)acetic acid methyl ester (160 mg, 0.33 mmol) in dioxan (2mL) is added an aqueous solutio of NaOH (1 M, 0.66 mL) and the mixture is stirred at 60°C for 1
-4816479
49/64 hour. The solvent is evaporated in vacuo, and the residue is suspended in water and treated with acetic acid (2 M). The precipitate is dryfreezed, dissolved in methanol and few dimethylformamide, and the product is precipitated with a few water, filtered and dried to yield 137 mg of the title compound (ESI mass spectrum: [M+Hf = 467; Rétention time HPLC: 0.89 min (method D)).
’H-NMR 400 MHz (DMSO-d6): δ [ppm] = 1.30 (t, 6H), 2.04 (s, 3H), 2.13 (s, 3H), 3.25 (s, 2H), 4.55 (q,4H), 5.16 (s, 2H), 6.97 (t, 1H), 7.17 (t, 1H), 7.29 (s, 1H), 7.47 (m, 1H), 7.62 (dd, 1H), 7.74 (d, 1H), 10.52 (s, 1H).
Compound 33: (1-(4-[(7-Chloro-3-methylbenzofuran-2-carbonyl)amino]benzyl)-3,5-dimethyl1H-pyrazol-4-yî)acetic acid (Coupling method C4):
a) To a solution of 7-chloro-3~methylbenzofuran-2-carboxylic acid (185 mg, 0.88 mmol) in 6 mL dichloromethane is added oxalyl chioride (0.123 mL, 1.14 mmol) and a drop of dimethylformamide. After stirring at room température for 1 hour the solvent is removed by évaporation in vacuo. The residue ts dissolved in dichloromethane (5 mL) and dropped to a solution of [1-(4-aminobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl]acetic acid tert-butyl ester (428 mg, 1 mmol) in form ofthe toluenesulphonate saitand diisopropylethylamine (0.39 mL, 2.27 mmol) in dichloromethane (5 mL). After addition of 4-dimethylaminopyridine (11 mg, 0.09 mmol) the solution is stirred at room température for 12 hours. The solution is extracted twice with hydrochloric acid (1 M), twice with water, twice with an aqueous solution of NaOH (1 M) and twice with water. The organic layer is dried over MgSO4, filtered and the solvent is evaporated in vacuo to yield 426 mg of (1-(4-[(7-chloro-3-methyl-benzofuran-2carbonyl)amino]benzyl)-3,5-dimethyl-1H-pyrazol-4-yl)acetic acid tert-butyl ester (ESI mass spectrum: [M+Hf = 508; Rétention time HPLC: 1.60 min (method H)).
b) To a solution of (1-(4-[(7-chloro-3-methyl-benzofuran-2-carbonyl)amino]benzyl)-3,5dimethyl-1H-pyrazol-4-yl)acetic acid tert-butyl ester (426 mg, 0.84 mmol) in dichloromethane (10mL) is added trifluoroacetic acid (400 mL, 5.2 mmol) and the mixture is stirred at room température for 3 days. The solvent is evaporated in vacuo, and the residue is suspended in water and treated with diethylether and the precipitating product is filtered off to yield 174 mg of the title compound (ESI mass spectrum: [M+H]* = 452; Rétention time HPLC: 1.39 min (method J)).
-4916479
50/64 ’H-NMR 400 MHz (DMSO-d6): δ [ppm] = 2.07 (s, 3H), 2.14 (s, 3H), 2.57 (s, 3H), 3.29 (s, 2H), 5.17 (s, 2H), 7.12 (d, 2H), 7.38 (t, 1H), 7.62 (d, 1H), 7.74 (d, 2H), 7.76 (d, 1 H). 10.33 (s, 1H).
Compound 48: (1-(4-[(3-Ethyl-5-fluorobenzofuran-2-carbonyl)amino]benzyl)-3,5-dimethyl-1Hpyrazol-4-yl)-acetic acid (Coupling method C4)
a) To a solution of 3-ethyl-5-fluorobenzofuran-2-carboxylic acid (450 mg, 2.16 mmol) in 10 mL dichloromethane is added oxalyl chloride (0.335 mL, 3.1 mmol) and a drop dimethylformamide. After stirring at room température for 1 hour the solvent is removed by évaporation in vacuo. The residue is dissolved in dichloromethane (10 mL) and dropped to a solution of [1-(4“aminobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl]acetic acid tert-butyl ester (1.054 g, 2.16 mmol) in the form of the 4-toluenesulphonate sait and diisopropylethylamine (1.3 mL, 7.57 mmol) in dichloromethane (5 mL). After addition of 4-dimethylaminopyridine (26.4 mg, 0.216 mmol) the solution is stirred at room température for 12 hours. The solvent is evaporated in vacuo, dissolved in 100 mL ethyl acetate, and the solution is extracted twice with water, once with hydrochloric acid (0.5 M), once with water, once with an aqueous solution of NaHCO3 (5% by weight) and once with water. The organic layer is dried over MgSO4, filtered and the solvent is evaporated in vacuo. The residue is purified by MPLC (dichloromethane/methanol 98:2) to yield 150 mg of 1-(4-[(3-ethyl-5-fluorobenzofuran-2carbonyl)aminoJbenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-acetic acid tert-butyl ester (ESI mass spectrum: [M+Hf = 506; Rétention time HPLC: 1.02 min (method D)).
b) To a solution of 1-(4-[(3-ethyl-5-fluorobenzofuran-2-carbonyl)amino]benzyl)-3,5-dimethyl1H-pyrazol-4-yl)-acetic acid tert-butyl ester (150 mg, 0.30 mmol) in acetonitrile (25mL) is added montmorillonite KSF (300 mg) and the mixture is refluxed for 6 hours. The mixture is diluted to 400 mL with acetonitrile, refluxed for 5 minutes and filtered. The solvent is evaporated in vacuo and the residue is washed with dimethylformamide (300 mL). After filtration the solvent is removed by évaporation and the residue is treated with acetone (200 mL). After trituration the precipitate is filtered off and washed with acetone to yield 112 mg of the title compound (ESI mass spectrum: [M+H]+ = 450; Rétention time HPLC: 0.85 min (method E)).
1H-NMR 400 MHz (DMSO-d6): δ [ppm] = 1.21 (t, 6H), 2.04 (s, 3H), 2.11 (s, 3H), 3.09 (q, 4H), 3.27 (s, 2H), 5.16 (s, 2H), 7.09 (d, 2H), 7.33 (t, 1 H), 7.67 (m, 2H), 7.76 (d, 2H), 10.39 (s, 1H).^<“
-5016479
51/64
Compounds 34 to 47 and 49 to 56 of table 1 below have likewise been prepared in analogy to coupling method C4 using suitable starting amines and carboxylic acids.
IV) BIOLOGICAL ASSAYS
The compounds of formula (la) and (lb) according to the invention were tested using the following biological test methods to détermine their ability to displace PGD2 from the CRTH2 receptor and for their ability to antagonise the functîonal effects of PGD2 at the CRTH2 receptor in a whole system.
PREPARATION OF HUMAN CRTH2 RECEPTOR MEMBRANES AND RADIOLIGAND BINDING ASSAY
The binding of CRTH2 antagonists is determined using membranes prepared from Chinese hamster ovary cells (CHO-K1 cells) transfected with the human CRTH2 receptor (CHO-K1hCRTH2 cells, Perkin Elmer, Cat No ES-561-C). To produce cell membranes the CHO-K1hCRTH2 cells are cultured in suspension in CHO SFMII medium supplemented with 400 pg/ml G418. The cells are harvested by centrifugation at 300 g for 10 min at room température. The cell pellet is resuspended in Phosphate Buffer Saline (PBS) including a protease inhibitor mix (Complété, Roche) and adjusted to a concentration of 10E7 cells/ml.
The CHO-K1-hCRTH2 cells are disrupted by nitrogen décomposition to obtain the membrane préparation. Cell débris is removed by centrifugation (500 g at 4°C, 30 min) and the supernatant is transferred into fresh tubes followed by a second centrifugation at 40000 g for 1 h at 4 °C to sédiment the membranes. The membranes are suspended in SPA incubation buffer (50mM Tris HCl, 10 mM MgCI21 150 mM NaCI, 1 mM EDTA, pH 7.4) without bovine sérum albumin, homogenized by passing through a single use needle (Terumo, 23Gx1), and stored in aliquots at -80 °C.
The CRTH2 receptor binding assay is performed in a scintillation proximity assay (SPA) format with the radioligand [3H]-PGD2 (Perkin Elmer, NET616000MC). CHO-K1-hCRTH2 cell membranes are again homogenized by passing through a single use needle (Terumo, 23Gx1) and diluted in SPA incubation buffer in suitable concentrations (0.5 -10 pg protein/well). The SPA assay is set up in 96 well microtiter plates (Perkin Elmer, CatNo. 6005040) in SPA incubation buffer with a final volume of 200 pl per well and final
-5116479
52/64 concentration of 50 mM Tris-HCI, 10 mM MgCI2, 150 mM NaCI, 1 mM EDTA pH 7,4, 0,1% bovine sérum albumin). The SPA assay mixture contains 60 pl of the membrane suspension, 80 μΙ of Wheat Germ Agglutinin coated PVT beads (GE Healthcare, RPNQ-0001, 0.3 mg/well), 40 μΙ of [3H]-PGD2 diluted in SPA buffer to a final concentration of 1 nM (50 000 dpm) and 20 μΙ of the test compound (dissolved in dimethylsulfoxid). The SPA assay mixture is incubated for 3 h at room température. Bound radioactivity is determined with a scintillation counter (Micro Beta Trilux, Wallac).
The binding of [3H]-PGD2 to CHO-K1-hCRTH2 cell membranes is determined in the absence (total binding, Bo) and presence (non-specific binding, NSB) of unlabelled PGD2 (1 μΜ, Cayman Chemical, Cat No 12010) or a reference CRTH2 antagonist (10 μΜ CAY10471, Cayman Chemical, Cat No 10006735).
Détermination of the affinity of a test compound is calculated by subtraction of the nonspecific binding (NSB) from the total binding (Bo) or the binding in the presence of the test compound (B) at a given compound concentration. The NSB value is set to 100% inhibition. The Bo-NSB value is set to 0% inhibition.
% inhibition values were obtained at a defined compound concentration, e.g. at 1 μΜ, % inhibition ofthe test compound was calculated by the formula 100-((B-NSB)*100/(BoNSB)). % inhibition values above 100% are founded by assay variance.
The dissociation constant K, was calculated by itérative fitting of experimental data obtained at several compound concentrations over a dose range from 0.1 to 30 000 nM using the law of mass action based program easy sys (Schittkowski, Num Math 68, 129-142 (1994)).
CRTH2 CAMP FUNCTIONAL ASSAY PROTOCOL
The assay is conducted in CHO-K1-hCRTH2 cells. Intracellular cAMP is generated by stimulating the cells with 10 μΜ Forskolin, an adenylate cyclase activator. PGD2 is added to activate the CRTH2 receptor which results in the atténuation of the forskolin-induced cAMP génération. Test compounds are tested for their ability to inhibit the PGD2-mediated atténuation of the Forskolin-induced cAMP génération in CHO-K1-hCRTH2 cells. CHO-K1-hCRTH2 cells are cultured in roller bottles in CHO SFMII medium supplemented with 400ug/ml G418. The cells are harvested by centrifugation at 300 g for 10 min at room
-5216479
53/64 température. The cell pellet is washed and suspended in PBS. The cells are adjusted to a final concentration of 4x10E6 cells/ ml.
Test compounds are diluted in dimethylsulfoxid and tested at several compound concentrations over a dose range from 0.1 to 3 000 nM.
The cAMP levels are determined by an AlphaScreen cAMP assay (Perkin Elmer CatNo. 6760625M) in 384 well optiplates (PerkinElmer, CatNo. 6007290) with a total assay volume of 50 μΙ. 10 μΙ of cells (40.000 cells per well) are incubated for 30 min at 37 °C with 10 μΙ of a stimulation mix containing a final concentration of 10μΜ Forskolin, 30 nM PGD2, 0.5 mM IBMX, 5 mM HEPES, IxHBSS buffer, 0.1% BSA, adjusted to pH 7.4, and the test compound at various concentrations. Thereafter, 30 μΙ of a lysis and détection mix is added containing SA donor beads, biotinylated cAMP, anti-cAMP acceptor beads, 0.3% Tweeen-20, 5 mM HEPES, 0.1% BSA, adjusted to pH 7.4. After 2 h incubation time the AlphaScreen signal is read on an AlphaQuest-HTS instrument. The IC50 values are calculated by using the Prism software.
OTHER CRTH2 FUNCTIONAL ASSAY PROTOCOLS
The ability of the tested compounds to antagonise the functional effects of PGD2 at the CRTH2 receptor may also be demonstrated by methodology known in the art, such as by a whole cell binding assay, a GTPgS assay, a BRET assay, an inositol phosphate accumulation assay, an CRTH2 cell surface expression assay, a Ca2+ influx assay, an ERK phosphorylation assay, an cell migration assay, an eosinophil shape change assay, a Th2 cell degranulation assay, or a basophil activation assay as described by Mathiesen et al., Mol Pharmacol. 2005, 68:393-402; Mimura et al., J. Pharmacol. Exp. Ther., 2005, 314:244-51; Sandham étal., Bioorg. Med. Chem. Lett., 2007,17:4347-50; Sandham Bioorg. Med. Chem. Lett, 2009,19:4794-8; Crosignani étal., J Med Chem, 2008, 51:2227-43; Royer étal., Eur J Clin Invest, 2008, 38:663-71; Boehme et al., Int Immunol, 2009, 21:621-32; Sugîmoto étal., Pharmacol. Exp. Ther., 2003, 305:347-52; Monneretetal., J Pharmacol Exp Ther, 2005, 312:627-34; Xue et al., J. Immunol., 2005,175:6531-6.
Cell lines for expressing the CRTH2 receptor include those naturally expressing the CRTH2 receptor, such as AML14.3D10 and NCI-H292 cells (Sawyer et al., Br. J. Pharmacol., 2002, 137:1163-72; Chiba et al., Int. Arch. Allergy. Immunol., 2007,143 Suppl 1:23-7), those induced to express the CRTH2 receptor by the addition of chemicals, such as HL-60 or AML14.3D10 cells treated with, for example, butyric acid (Sawyer et al., Br. J. Pharmacol., γ/
-5316479
54/64
2002, 137:1163-72) or a cell line engineered to express a recombinant CRTH2 receptor, such as L1.2, CHO, HEK-293, K562 or CEM cells (Liu et al., Bioorg. Med. Chem. Lett., 2009,19:6840-4; Sugimoto et al., Pharmacol Exp Ther, 2003, 305:347-52; Hata et al., Mol. Pharmacol., 2005, 67:640-7; Nagata et al., FEBS Lett, 1999, 459:195-9).
Finally, blood or tissue cells, for example human peripheral blood eosinophils, isolated using methods as described by Hansel étal., J. Immunol. Methods., 1991, 145,105-110, or human Th2 cells isolated and treated as described by Xue et al., J. Immunol., 2005,175:6531-6, or human basophils isolated and characterized as described by Monneret et al., J. Pharmacol, Exp. Ther., 2005, 312:627-34 can be utilized in such assays.
In particular, the compounds of the présent invention hâve activity in binding to the CRTH2 receptor in the aforementioned assays and inhibit the activation of CRTH2 by CRTH2 ligands. As used herein, activity is intended to mean a compound demonstrating an inhibition of 50% at 1 μΜ or higher in inhibition, or a K| value < 1 μΜ, when measured in the aforementioned assays. Such a resuit is indicative of the intrinsic activity of the compounds as inhibitor of CRTH2 receptor activity. Antagoniste activities of selected compounds are shown in tables 1 and 2 below.
Table 1: Compounds of formula la”
Cmpd | “R3^ | R1 = R2 | Z | Ryl; RyZ; R*3; Ry4; Ry5 | MS [M+Hf | Rétention Time | Ki [nM] |
1 | F | ch3 | NH | H; H; H; H; H | 421 | 1.04 method G | 0.8 |
2 | Cl | ch3 | NH | H; H; H; H; H | 437 | 1.36 min method B | 0.5 |
3 | F | ch3 | nch2- CeH5 | H; H; H; H; H | 511 | 0.98 min method D | 0.2 |
4 | H | ch3 | O | CH3; H; F; H; H | 436 | 0.85 min method D | 0.8 |
-5416479
55/64
Cmpd | R1 = R2 | Z | Ry1; Ryi; Ry3; Ry4; Rys | MS [M+H]+ | Rétention Time | Ki [nM] | |
5 | Cl | ch3 | 0 | H; H; H; H; H | 438 | 0.86 min method D | 0.8 |
6 | H | ch3 | 0 | H; H; OCH3; H; H | 434 | 0.77 min method D | 0.6 |
7 | H | ch3 | 0 | CH3; H; H; H; F | 436 | 0.86 min method D | 1.3 |
8 | H | ch3 | 0 | H; H; CI; H; H | 438 | 0.84 min method D | 0.3 |
9 | H | ch3 | 0 | H; H; H; H; OCH3 | 434 | 0.78 min method D | 1.2 |
10 | H | ch3 | NH | H; H; H; H; H | 403 | 1.24 min method B | 0.2 |
11 | H | ch3 | NH | H; H; H; F; H | 421 | 0.76 min method D | 0.2 |
12 | H | ch3 | NH | H; H; F; H; H | 421 | 0.76 min method D | 0.2 |
13 | H | ch3 | nch3 | CH3; H; H; H; H | 431 | 0.81 min method D | 63.9 |
14 | H | ch3 | NH | CH3; H; OCH3; H; H | 447 | 0.79 min method D | 0.1 |
15 | H | ch3 | S | H; H; H; H; H | 420 | 1.32 min method B | 0.3 |
16 | H | ch3 | NCH3 | H; H; H; H; H | 417 | 1.29 min method K | 0.8 |
17 | H | ch3 | NC2H5 | H; H; H; H; H | 431 | 1.35 min method K | 0.4 |
18 | H | ch3 | nch2CeHs | H; H; H; H; H | 493 | 0.88 min method D | < 0.1 |
19 | H | c2h5 | 0 | H; H; Cl; H; H | 466 | 1.43 min method K | 0.2 |
20 | H | c2hs | NH | H; H; H; H; H | 431 | 1.30 min method K | 0.3 |
21 | H | c2h5 | nch3 | H; H; H; H; H | 445 | 0.84 min method D | 0.3 |
22 | H | c2h5 | nc2h5 | H; H; H; H; H | 459 | 0.87 min method D | 0.2 |
23 | H | C2H5 | NH | H; H; F; H; H | 449 | 0.80 min method D | 0.3 |
24 | H | c2h5 | nch3 | CH3; H; H; H; H | 459 | 0.84 min method D | 9.9 |
25 | H | c2h5 | NH | H; H; H; F; H | 449 | 1.34 min method K | 0.2 |
26 | H | ch3 | 0 | H; H; H; H; H | 404 | 1.28 min method B | 0.8 |
27 | F | ch3 | 0 | CH3; H; F; H; H | 454 | 0.90 min method D | 0.6 |
28 | H | ch3 | N(CH2)2 -ch3 | H; H; H; F; H | 463 | 0.85 min method E | 0.1 |
-5516479
56/64
Cmpd | R3' | R1 = R2 | Z | Ry1; RyZ; R*3; Ry4; RyS | MS [M+H]* | Rétention Time | Ki [nM] |
29 | H | ch3 | nc2h5 | H; H; H; F; H | 449 | 0.84 min method E | 0.1 |
30 | F | ch3 | nch3 | H; H; H; H; H | 435 | 0.85 min method C | 1.0 |
31 | F | ch3 | nc2h5 | H; H; H; H; H | 449 | 0.85 min method C | 0.2 |
32 | F | ch3 | NC2Hs | H; H; F; H; H | 467 | 0.89 min method D | 0.2 |
33 | H | ch3 | 0 | CH3; H; H; H; Cl | 452 | 1.39 min method J | 2.2 |
34 | H | ch3 | 0 | CH2CH3; H; H; H; F | 450 | 1.38 min method L | 0.3 |
35 | H | ch3 | 0 | CH2CH3; H; F; H; F | 468 | 1.43 min method L | 0.3 |
36 | H | ch3 | 0 | H; H; H; Cl; H | 438 | 1.32 min method M | 0.2 |
37 | F | ch3 | 0 | CH3; H; H; H; Cl | 470 | 1.46 min method J | 2.2 |
38 | F | ch3 | 0 | CH2CH3; H; H; H; F | 468 | 0.88 min method E | 0.6 |
39 | F | ch3 | 0 | H; H; H; Cl; H | 456 | 1.40 min method M | 0.4 |
40 | F | ch3 | nc2h5 | H; F; H; H; H | 467 | 0.87 min method E | 0.4 |
41 | F | ch3 | nc2h5 | H; H; H; F; H | 467 | 0.87 min method E | 0.1 |
42 | F | ch3 | N(CH2)zch3 | H; H; H; F; H | 481 | 0.89 min method E | 0.1 |
43 | F | ch3 | 0 | CH2OCH3; H; H; H; H | 466 | 0.86 min method D | 2.3 |
44 | F | ch3 | o | CH3; H; Cl; H; H | 470 | 0.95 min method D | 0.3 |
45 | F | ch3 | o | CH3; H; Br; H; H | 514 | 0.96 min method D | 0.3 |
46 | F | ch3 | s | CH3; H; F; H; H | 470 | 0.88 min method D | 4.5 |
47 | F | ch3 | 0 | CH2CH3; H; F; H; H | 468 | 0.94 min method D | 0.9 |
48 | H | ch3 | 0 | CH2CH3; H; F; H; H | 450 | 0.85 min method E | 1.2 |
49 | F | ch3 | 0 | CH3; H; OCH3; H; H | 466 | 1.30 min method F | 0.1 |
50 | F | ch3 | 0 | CH3; H; H; H; F | 454 | 1.32 min method F | 0.4 |
51 | F | ch3 | nch3 | H; H; F; H; H | 453 | 1.28 min method F | 0.4 |
52 | F | ch3 | 0 | (CH2)2CH3; H; F; H; H | 482 | 0.87 min method D | 0.7 |
53 | F | ch3 | N(CH2)3ch3 | H; H; H; H; H | 477 | 1.41 min method O | 0.2 |
-5616479
57/64
Cmpd | R3' | R1 = R2 | Z | Ry1; RyZ; Ry3; Ry4; Ry5 | MS [M+Hf | Rétention Time | Ki [nM] |
54 | F | ch3 | N(CH2)2ch3 | H; H; F; H; H | 481 | 0.92 min method D | 0.2 |
55 | F | ch3 | N(CH2)3ch3 | H; H; F; H; H | 495 | 0.91 min method E | 0.1 |
56 | F | ch3 | N(CH2)2ch3 | H; H; H; H; H | 463 | 0.87 min method E | 0.2 |
Table 2: Compounds of formula Ib”
R»3
Cmpd | R1,R2 | R3’ | Z | Ry1; Ryz; Ry3; Ry4; Ry5 | MS [M+H]+ | Rétention Time | Ki [nM] |
57 | ch3 | H | O | H; H; H; H; H | 404 | 1.29 min method B | 8.8 |
58 | ch3 | H | NH | H; H; H; H; H | 403 | 1.14 min method B | 37.2 |
59 | ch3 | H | S | H; H; H; H; H | 420 | 1.32 min method B | 3.8 |
:o*5JüfL 2013
-5716479
Claims (23)
1. Pyrazole compounds of formula (la) or (lb) and pharmaceutically acceptable salts thereof, wherein
Ra and Rb are independently selected hydrogen, hydroxy, halogen, CrCe-alkyl, CrC8 haloalkyl, CrCe-alkoxy, Ci-C6-haloalkoxy and C3-C8-cycloalkylt or Ra and Rb together with the carbon atom they are bound to form may form a carbonyl group, or Ra and Rb together with the carbon atom they are bound to form a 3to 8-membered ring, wherein said ring may contain 1 or 2 heteroatoms selected from O, N and S as ring member and wherein the ring members of said ring may optionally be independently substituted by hydroxy, halogen, CiC6-alkyl, Ci-C6-haloalkyl, CrCe-alkoxy, CrC6-haloalkoxy and C3-C8-cycloalkyl;
Rc and Rd are independently selected hydrogen, hydroxy, halogen, Ci-C6-alkyl, CrCehaloalkyl, CrCe-alkoxy, CrC6-haloalkoxy and C3-C8-cycloalkyl, or Rc and Rd together with the carbon atom they are bound to form may form a carbonyl group, or Rc and Rd together with the carbon atom they are bound to form a 3to 8-membered ring, wherein said ring may contain 1 or 2 heteroatoms selected from O, N and S as ring member and wherein the ring members of
-5816479
59/64 said ring may optionally be independently substituted by hydroxy, halogen, Cr
C0-alkyl, CrCe-haloalkyl, CrCe-alkoxy, CrC6-haloalkoxy and C3-C8-cycloalkyl;
Y1, Y2, Y3, Y4 and Y5 are independently selected from N and CRy, wherein each Ry is independently selected from H, hydroxy, halogen, cyano, nitro, SF5, C(O)NRfR9, Ci-C6-alkyl, hydroxy-CrCe-alkyl, Ct-Cg-alkoxy-CrCg-alkyl, C3- C8cycloalkyl, Cj-Cg-haloalkyl, CrC6-alkoxy, Ci-C6-alkoxy-CrC6-alkoxy, Ci-C0haloalkoxy, C3-CB-cycloalkoxy, C-i-Ce-alkylamino, di-Ci-C6-alkylamino, Ci-C0alkylsulfonyl, phenyl, phenoxy, 5- or 6-membered heterocyclyl and 5- or 6membered heterocyclyloxy, wherein Rf and R0 are independently from each other selected from H, CrC6-alkyl, CrC6-haloalkyl, C3-C0-cycloalkyl, C3-Cecycloalkenyl and 5- or 6-membered heterocyclyl or Rf and R3 together with the nitrogen atom to which they are bound form a cyclic amine, which may comprise a further heteroatom selected from O, N and S as a ring member;
Z is selected from O, S and NRZ, wherein Rz is H, Cr^-alkyl or benzyl;
R1 and R2 independently from each other are selected from H, halogen, CrCe-alkyl, C2-C6-alkenyl, C2-C0-alkynyl, CrC6-alkoxy, C1-C0-alkylthio, -NR'R9, C3-C0cycloalkyl, Cs-Ce-cycloalkyl-CrCe-alkyl, C3-C8-cycloalkyl-C2-C0-alkenyl, C3-C8cycloalkenyl, Cs-Ca-cycloalkenyl-CrCe-alkyl, C3-C8-cycloalkenyl-C2-C0-alkenyl, phenyl, phenyl-C^Ce-alkyl, phenyl-C2-C6-alkenyl, naphthyl, naphthyl-CrCsalkyl, naphthyl-C2-C0-alkenyl, heterocyclyl, heterocyclyl-Ci-C6-alkyl, and heterocyclyl-C2-C6-alkenyl, wherein the Ci-C6-alkyl, C2-C0-alkenyl and C2-C0-aikynyl moieties in the aforementioned radicals R1 and R2 are unsubstituted or carry at least one substituent selected from hydroxy, halogen, cyano, nitro, C1-C6-alkoxy, CrC6haloalkoxy, CrC6-alkylamino, di CrCg-alkylamino and CrC6-alkylsulfonyl and/or wherein two radicals bound to the same carbon atom of said CrC0-alkyl, C2C6-alkenyl and C2-C6-alkynyl moieties in the aforementioned radicals R1 and R2 together with said carbon atom may form a carbonyl group, and wherein
-5916479
60/64 the C3-C8-cycloalkyl, cycloalkenyl, phenyl, naphthyl and heterocyclyl moieties in the aforementioned radicals R1 and R2 are unsubstituted or carry at least one substituent selected from hydroxy, halogen, cyano, nitro, CrC6-alkyl, C3C8-cycloalkyl, Ci-C8-haloalkyl, CrC6-alkoxy, Ci-Ce-haloalkoxy, CrC6alkylamino, di-CrC6-alkylamino, CrCe-alkylsulfonyl, phenyl and 5- or 6membered hetaryl and/or wherein two radicals bound to the same carbon atom of said C3-C0-cycloalkyl, C3-Ce-cycloalkenyl and heterocyclyl moieties of the radicals R1 and R2 together with said carbon atom may form a carbonyl group, and wherein
Rf and R9 are independently from each other selected from H, Ci-C6-alkyl, Cr C6-haloalkyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl and heterocyclyl or
Rf and R9 together with the nitrogen atom to which they are bound form a cyclic amine, which may comprise a further heteroatom selected from O, N and S as a ring member;
n is an integer selected from 0, 1, 2 or 3; and
R3 if présent are selected independently from each other from halogen, ΟρΟβalkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, CrC6-haloalkoxy and C3-C8-cycloalkyl.
2. Pyrazole compounds of formula (la) or (lb) according to claim 1, wherein Ra and Rb are both hydrogen.
3. Pyrazole compounds of formula (la) or (lb) according to any of the preceding claims, wherein Rc and Rd are both hydrogen.
4. Pyrazole compounds of formula (la) or (lb) according to any of the preceding claims, wherein Y1 is CRy1 or N, wherein Ry1 has one of the meanings as defined for Ry in claim 1.
5. Pyrazole compounds of formula (la) or (lb) according to claim 4, wherein Y1 is CRy1.
-6016479
61/64
6. Pyrazole compounds of formula (la) or (lb) according to claim 5, wherein Ry1 is selected from H, CrCB-alkyl, CrC6-alkoxy-CrC6-alkyl and Ci-C6-haloalkyl.
7. Pyrazole compounds of formula (la) or (lb) according to any of the preceding claims, wherein Y2 is CR1'2, Y3 is CR*3, Y4 is CR*4 and Y5 is CR*5, wherein R*2, Ry3, Ry4 and R*5 independently from each other hâve one of the meanings as defined for Ry in claim 1.
8. Pyrazole compounds of formula (la) or (lb) according to claim 7, wherein Ry2, Ry3, Ry4 and R*5 are independently selected from H, halogen, CrCs-alkoxy, CrC6-alkoxy-Cr C6-alkoxy and CrC6-haloalkoxy.
9. Pyrazole compounds of formula (la) or (lb) according to any of the preceding claims, wherein Z is O.
10. Pyrazole compounds of formula (la) or (lb) according to any of claims 1 to 8, wherein ZisS.
11. Pyrazole compounds of formula (la) or (lb) according to any of claims 1 to 8, wherein Z is and NR1.
12. Pyrazole compounds of formula (la) or (lb) according to any of the preceding claims, wherein R1 and R2 independently from each other are selected from H, CrCB-alkyl, C3-CB-cycloalkyl, phenyl and naphthyl.
13. Pyrazole compounds of formula (la) or (lb) according to claim 12, wherein R1 and R2 independently from each other are selected from H, CrC4-alkyl, C3-C6-cycloalkyl and phenyl.
14. Pyrazole compounds of formula (la) or (lb) according to claim 13, wherein R1 and R2 are selected from CrC4-alkyl.
15. Pyrazole compounds of formula (la) or (lb) according to any of the preceding claims, wherein n is 0 or 1. ---6116479
62/64
16. Pyrazole compounds of formula (la) or (Ib) according to any of the preceding daims, wherein R3 if présent are independently selected from halogen.
17. Pyrazole compounds of formula (la) according to any of the preceding daims, wherein the pyrazole compounds are selected from compounds of formula (la’), wherein Z, R1, R2, R3, Ry1, R*2, Ry3, Ry4 and R75 hâve one of the meanings given in any of the preceding daims and n is 0 or 1.
18. Pyrazole compounds of formula (Ib) according to any of daims 1 to 16, wherein the pyrazole compounds are selected from compounds of general formula (Ib’), wherein Z, R1, R2, R3, Ry1, R*2, R*3, Ry4 and R16 hâve one of the meanings given in any of the preceding daims and n is 0 or 1.
19. Use of pyrazole compounds of formula (la) or (Ib) according to any of the preceding daims as médicaments.
20. Use of pyrazole compounds of formula (la) or (Ib) according to any of daims 1 to 18, for preparing a médicament for the treatment of diseases related to CRTH2 activity.
21. Use of pyrazole compounds of formula (la) or (Ib) according to any of daims 1 to 18 for preparing a médicament for the prévention and/or treatment of inflammatory,
-6216479
63/64 înfectious and immunoregulatory disorders, respiratory or gastrointestinal diseases or complaints, inflammatory diseases of the joints and allergie diseases of the nasopharynx, eyes, and skin.
5
22. Pharmaceutical formulations, containing one or more of the pyrazole compound of formula (la) and/or (Ib) according to any of ciaims 1 to 18.
23. Pharmaceutical formulations, containing one or more pyrazole compound of formula (la) and/or (Ib) according to any of ciaims 1 to 18 in combination with one or more io active substances selected from among betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, CCR3 antagonists, CCR5 antagonists, CCR9 antagonists, 5-LO inhibitors, histaminereceptor antagonists, SYK inhibitors and sulfonamides. uX
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11151876.7 | 2011-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16479A true OA16479A (en) | 2015-10-21 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2788224C (en) | Pyrazole compounds as crth2 antagonists | |
AU2012210718B2 (en) | Pyrazole compounds as CRTH2 antagonists | |
US9206164B2 (en) | Pyrazole compounds as CRTH2 antagonists | |
OA16479A (en) | Pyrazole compounds as CRTH2 antagonists. | |
NZ611695B2 (en) | Pyrazole compounds as crth2 antagonists |